[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 118
1. Pascual-Castroviejo I, Pascual-Pascual SI, Velázquez-Fragua R, Viaño J, Carceller F, Hernández-Moneo JL, Gutiérrez-Molina M, Morales C: [Subependymal giant cell astrocytoma in tuberous sclerosis complex. A presentation of eight paediatric patients]. Neurologia; 2010 Jun;25(5):314-21
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Subependymal giant cell astrocytoma in tuberous sclerosis complex. A presentation of eight paediatric patients].
  • [Transliterated title] Astrocitoma subependimario de células gigantes en el complejo de esclerosis tuberosa. Presentación de ocho pacientes infantiles.
  • OBJECTIVE: Presentation of 8 patients with subependymal giant-cell astrocytomas (SGCA) associated with tuberous sclerosis complex (TSC).
  • MATERIAL AND METHODS: There are 8 patients, 6 males and 2 females with TSC, who presented with the tumour between the neonatal period and 24 years.
  • Only one patient developed the tumour suddenly from pre-existing subependymal nodules from the childhood and they had to be removed at 24 years of age.
  • By contrast, 32 patients with TSC and images of subependymal nodules whose CT or MR progress was followed up for between 10 and 30 years did not develop a tumour.
  • [MeSH-major] Astrocytoma / etiology. Astrocytoma / pathology. Brain Neoplasms / etiology. Brain Neoplasms / pathology. Tuberous Sclerosis


2. Ahmad Z, Rauf F, Azad NS, Ahsan A: Subependymal giant cell astrocytoma. J Pak Med Assoc; 2006 Oct;56(10):463-5
Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal giant cell astrocytoma.
  • Subependymal giant cell astrocytomas (SEGAs) are slowly growing tumours corresponding to WHO grade I.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144395.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


3. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN: Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med; 2010 Nov 4;363(19):1801-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
  • BACKGROUND: Neurosurgical resection is the standard treatment for subependymal giant-cell astrocytomas in patients with the tuberous sclerosis complex.
  • METHODS: Patients 3 years of age or older with serial growth of subependymal giant-cell astrocytomas were eligible for this open-label study.
  • The primary efficacy end point was the change in volume of subependymal giant-cell astrocytomas between baseline and 6 months.
  • Everolimus therapy was associated with a clinically meaningful reduction in volume of the primary subependymal giant-cell astrocytoma, as assessed on independent central review (P<0.001 for baseline vs. 6 months), with a reduction of at least 30% in 21 patients (75%) and at least 50% in 9 patients (32%).
  • There were no new lesions, worsening hydrocephalus, evidence of increased intracranial pressure, or necessity for surgical resection or other therapy for subependymal giant-cell astrocytoma.
  • Single cases of grade 3 treatment-related sinusitis, pneumonia, viral bronchitis, tooth infection, stomatitis, and leukopenia were reported.
  • CONCLUSIONS: Everolimus therapy was associated with marked reduction in the volume of subependymal giant-cell astrocytomas and seizure frequency and may be a potential alternative to neurosurgical resection in some cases, though long-term studies are needed. (Funded by Novartis; ClinicalTrials.gov number, NCT00411619.).
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Seizures / drug therapy. Sirolimus / analogs & derivatives. Tuberous Sclerosis / drug therapy


Advertisement
4. Koenig MK, Butler IJ, Northrup H: Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol; 2008 Oct;23(10):1238-9
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex.
  • The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas.
  • Magnetic resonance imaging of the brain 2(1/2) months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left).

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Res. 2005 Jan;57(1):67-75 [15557109.001]
  • [Cites] BMC Dermatol. 2008;8:1 [18226258.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • (PMID = 18952591.001).
  • [ISSN] 1708-8283
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024149; United States / NCRR NIH HHS / RR / RR024149-05S1; United States / NCRR NIH HHS / RR / KL2 RR024149-05S1
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS282750; NLM/ PMC3072698
  •  go-up   go-down


5. Bongiorni L, Arroyo HA, Lubienicki F: [Subependymal nodules-sudependymal giant cell astrocytoma complex in children with tuberous sclerosis]. Medicina (B Aires); 2009;69(1 Pt 1):8-14
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Subependymal nodules-sudependymal giant cell astrocytoma complex in children with tuberous sclerosis].
  • [Transliterated title] Complejo nódulo subependimario-astrocitoma subependimario gigantocelular en niños con esclerosis tuberosa.
  • The object of this paper is to describe the imaging and clinical characteristics of subependymal nodule (SN) - subependymal giant cell astrocytoma (SGCA) complex in tuberous sclerosis and analyze its evolution in order to attempt early detection and the prevention of intracranial hypertension.
  • Six patients presented visual deficit and in these, the average diameter of the tumor was 31.5 mm, a high value when compared to 18.7 mm in the patients without visual deficit.
  • The imaging and clinical follow-up of any subependymal lesion close to the foramen of Monro will permit, at a presymptomatic stage, an anticipation of surgical treatment thus reducing intracranial hypertension incidence.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Ventricles / pathology. Tuberous Sclerosis / pathology


6. Timotin L, Sarrot-Reynauld F, Lantuejoul S, Pasquier B, Massot C, Ashraf A, Borgel F: [Tuberous sclerosis without mental impairment, diagnosed in adulthood]. Rev Med Interne; 2005 Jun;26(6):511-3
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXEGESIS: We report a case of TSC diagnosed in a 33-year-old man, without any known family history of phakomatosis, presenting with facial angiofibromas, hypomelanotic macules, a giant-cell astrocytoma and retinal phakomas without any mental impairment or epilepsy.
  • CONCLUSION: TSC may occur in patients who do not have any family history of phakomatosis because de novo mutations are frequent.
  • They should lead to brain imaging in search for astrocytoma, subependymal nodules and cortical tubers which number is directly correlated with the risk of seizures and the degree of mental impairment.

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936480.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Berhouma M: Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective. World J Pediatr; 2010 May;6(2):103-10
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of subependymal giant cell tumors in tuberous sclerosis complex: the neurosurgeon's perspective.
  • BACKGROUND: Tuberous sclerosis complex (TSC), an autosomal dominant genetic disorder, can lead to the development of hamartomas in various organs, including the heart, lungs, kidneys, skin and brain.
  • The management of subependymal giant cell tumors (SGCTs) is still controversial, and peri- and/or intraventricular neoplasms may lead to life-threatening hydrocephalus.
  • The data were collected after a bibliography made using PubMed/Medline with these terms: subependymal, subependymal giant cell astrocytoma, subependymal giant cell tumor, and tuberous sclerosis complex.
  • RESULTS: SGCTs are shown to be generated from a glioneuronal lineage, but their filiation with subependymal nodules (SENs) is still under debate.
  • CONCLUSIONS: An earlier diagnosis of SGCT in neurologically asymptomatic children with TSC may allow a precocious surgical removal of the tumor before the installation of increased intracranial pressure signs, an attitude that is being progressively adopted to lessen the morbimortality rate.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Tuberous Sclerosis / complications
  • [MeSH-minor] Algorithms. Child. Humans. Hydrocephalus / etiology. Intracranial Hypertension / etiology. Mutation. Neurosurgical Procedures. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1992 Sep;2(1):37-41 [1303246.001]
  • [Cites] Am J Hum Genet. 1999 Apr;64(4):986-92 [10090883.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]
  • [Cites] Neurosurgery. 1984 Jan;14 (1):93-8 [6363964.001]
  • [Cites] Pediatr Neurosurg. 1995;23(3):115-21 [8751291.001]
  • [Cites] Pediatr Neurol. 2007 Feb;36(2):128-31 [17275668.001]
  • [Cites] Neurosurg Rev. 2004 Oct;27(4):274-80 [15309659.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):73-9 [18177819.001]
  • [Cites] Hum Mol Genet. 1998 Jun;7(6):1053-7 [9580671.001]
  • [Cites] Epilepsia. 2007 Aug;48(8):1625-8 [17484758.001]
  • [Cites] Psychol Med. 2003 Feb;33(2):335-44 [12622312.001]
  • [Cites] Brain Dev. 2001 Nov;23(7):624-34 [11701267.001]
  • [Cites] Arch Dis Child. 2008 Sep;93(9):728-31 [18456700.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):812-6 [14871804.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Aug;13(4):295-8 [7547639.001]
  • [Cites] Kidney Int. 2006 Nov;70(10):1777-82 [17003820.001]
  • [Cites] Pediatr Radiol. 1992;22(7):485-9 [1491903.001]
  • [Cites] Pediatrics. 2006 Oct;118(4):e1146-51 [16940165.001]
  • [Cites] Pathol Oncol Res. 2004;10(4):219-24 [15619643.001]
  • [Cites] BJU Int. 2004 Oct;94(6):853-7 [15476522.001]
  • [Cites] J Child Neurol. 2008 Oct;23(10):1238-9 [18952591.001]
  • [Cites] Pediatr Neurol. 2003 Nov;29(5):404-9 [14684235.001]
  • [Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]
  • [Cites] J Med Genet. 1996 Nov;33(11):962-4 [8950679.001]
  • [Cites] N Engl J Med. 1999 Mar 4;340(9):703-7 [10053179.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:125-7 [2039137.001]
  • [Cites] Arch Dis Child. 2004 Jun;89(6):530-3 [15155396.001]
  • [Cites] Childs Nerv Syst. 1995 Jun;11(6):335-9 [7671268.001]
  • [Cites] Neurosurg Rev. 1980;3(2):139-50 [7231685.001]
  • [Cites] Dev Med Child Neurol. 1996 Feb;38(2):146-55 [8603782.001]
  • [Cites] Childs Nerv Syst. 2003 Apr;19(4):232-43 [12715190.001]
  • [Cites] Lancet. 1987 Mar 21;1(8534):659-61 [2882085.001]
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] Childs Nerv Syst. 1985;1(1):45-8 [3986841.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Mar;66(3):370-5 [10084537.001]
  • [Cites] Arch Dis Child. 2008 Sep;93(9):751-4 [18456692.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):328-32 [7894481.001]
  • [Cites] Respir Med. 2002 Jan;96(1):1-6 [11863203.001]
  • [Cites] J Neurooncol. 2001 May;52(3):217-25 [11519851.001]
  • [Cites] Childs Nerv Syst. 1989 Feb;5(1):43-4 [2702677.001]
  • [Cites] Neurosurgery. 2007 Jan;60(1):83-89; discussion 89-90 [17228255.001]
  • [Cites] Hum Mol Genet. 1997 Nov;6(12):2155-61 [9328481.001]
  • [Cites] Arch Neurol. 2000 May;57(5):662-5 [10815131.001]
  • [Cites] Hum Mol Genet. 1994 Oct;3(10):1829-32 [7849708.001]
  • [Cites] Radiology. 1992 Apr;183(1):227-38 [1549677.001]
  • [Cites] Neurosurgery. 1991 Jun;28(6):864-8 [2067610.001]
  • [Cites] Pediatr Neurosurg. 1994;20(4):233-9 [8043461.001]
  • [Cites] Surg Neurol. 1977 Aug;8(2):99-101 [888093.001]
  • [Cites] Neuropediatrics. 1997 Oct;28(5):244-52 [9413002.001]
  • [Cites] Mod Pathol. 1997 Apr;10(4):313-7 [9110292.001]
  • [Cites] Cancer Biol Ther. 2003 Sep-Oct;2(5):471-6 [14614311.001]
  • [Cites] Neurology. 2004 Oct 26;63(8):1457-61 [15505165.001]
  • [Cites] J Child Neurol. 1998 Apr;13(4):173-7 [9568761.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • [Cites] Pediatr Neurol. 2004 Oct;31(4):239-47 [15464634.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):880-3 [3286833.001]
  • (PMID = 20490765.001).
  • [ISSN] 1867-0687
  • [Journal-full-title] World journal of pediatrics : WJP
  • [ISO-abbreviation] World J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 60
  •  go-up   go-down


8. de Carvalho Neto A, Gasparetto EL, Bruck I: Subependymal giant cell astrocytoma with high choline/creatine ratio on proton MR spectroscopy. Arq Neuropsiquiatr; 2006 Sep;64(3B):877-80
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal giant cell astrocytoma with high choline/creatine ratio on proton MR spectroscopy.
  • OBJECTIVE: To report a case of subependymal giant cell astrocytoma (SEGA) in a patient with tuberous sclerosis, emphasizing the proton MR spectroscopy (MRS) findings.
  • MRI showed many cortical tubers and subependymal nodules.
  • As a consequence, MRS may be a valuable tool for the early detection of neoplastic transformation of subependymal nodules near the foramina of Monro in patients with tuberous sclerosis.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Choline / analysis. Creatine / analysis. Tuberous Sclerosis / complications
  • [MeSH-minor] Biomarkers, Tumor / analysis. Child, Preschool. Humans. Magnetic Resonance Spectroscopy. Male


9. You H, Kim YI, Im SY, Suh-Kim H, Paek SH, Park SH, Kim DG, Jung HW: Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma. J Neurooncol; 2005 Aug;74(1):1-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical study of central neurocytoma, subependymoma, and subependymal giant cell astrocytoma.
  • For investigation of histogenesis of central neurocytomas (CNs), subependymoma (SEs), subependymal giant cell astrocytomas (SEGAs), we studied expression of various neuronal and glial biomarkers by immunohistochemical (IHC) study and reverse transcriptase-polymerase chain reaction (RT-PCR).
  • Control group was five ependymomas (EPs) and four pilocytic astrocytomas (PAs).
  • Conclusively, coexpression of neuronal and glial markers and expression of nestin in CNs, SEGAs and SEs suggested the origin of these tumor cells might be the stem cells being able to differentiate into both neuronal and glial phenotypes.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Glioma, Subependymal / metabolism. Neurocytoma / metabolism

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1996 Jan;45(1):49-56 [9190699.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;58(2):95-121 [2575822.001]
  • [Cites] Lab Invest. 1992 Mar;66(3):303-13 [1538585.001]
  • [Cites] J Neurosurg. 1992 May;76(5):759-65 [1564538.001]
  • [Cites] Exp Neurol. 1999 Apr;156(2):333-44 [10328940.001]
  • [Cites] Cancer. 1974 Dec;34(6):1992-2008 [4434329.001]
  • [Cites] J Neurosci Res. 1998 Feb 15;51(4):526-35 [9514206.001]
  • [Cites] J Neurosurg. 1984 Jun;60(6):1121-33 [6202856.001]
  • [Cites] Arch Pathol Lab Med. 1999 Apr;123(4):306-9 [10320142.001]
  • [Cites] Acta Neuropathol. 1997 Nov;94(5):425-35 [9386774.001]
  • [Cites] Acta Neuropathol. 1996;91(4):368-75 [8928613.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):583-8 [1885976.001]
  • [Cites] J Neurosci. 1999 Jun 1;19(11):4462-71 [10341247.001]
  • [Cites] Hum Pathol. 1986 Oct;17(10):979-83 [3093369.001]
  • [Cites] Pol J Pathol. 1997;48(3):189-95 [9401412.001]
  • [Cites] Neuron. 1994 Nov;13(5):1071-82 [7946346.001]
  • [Cites] J Neurooncol. 2001 May;52(3):217-25 [11519851.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):210-4 [7816819.001]
  • [Cites] Acta Cytol. 1987 Nov-Dec;31(6):815-24 [3425142.001]
  • [Cites] Acta Neuropathol. 1995;90(4):387-99 [8546029.001]
  • [Cites] Mol Cell Neurosci. 1999 Jun;13(6):450-64 [10383830.001]
  • [Cites] J Clin Neurosci. 2001 Jan;8(1):31-4 [11322123.001]
  • (PMID = 16078101.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


10. Kawaguchi T, Kumabe T, Shimizu H, Watanabe M, Tominaga T: 201Tl-SPECT and 1H-MRS study of benign lateral ventricle tumors: differential diagnosis of subependymoma. Neurosurg Rev; 2005 Apr;28(2):96-103
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 201Tl-SPECT and 1H-MRS study of benign lateral ventricle tumors: differential diagnosis of subependymoma.
  • Our study includes nine cases of benign lateral ventricle tumors including two cases of central neurocytoma, two of subependymal giant cell astrocytoma, two of pilocytic astrocytoma and three of subependymoma treated surgically between 1996 and 2003.
  • All three types of tumor demonstrated heterogeneous enhancement on MR imaging with gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) and increased choline (Cho) peak and decreased N-acetyl aspartate (NAA) and creatine (Cre) peaks on (1)H-MRS. (201)Tl-SPECT showed high uptake of (201)Tl without wash out in all cases of central neurocytoma, subependymal giant cell astrocytoma and pilocytic astrocytoma, but no uptake in cases of subependymoma.
  • Absence of (201)Tl uptake in contrast with enhancement on MR imaging and the (1)H-MRS features of modest elevation of the Cho/Cre ratio, reduction of the NAA peak and presence of lactate/lipid peaks are characteristic features of subependymomas and useful to establish a preoperative diagnosis.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebral Ventricle Neoplasms / diagnosis. Glioma, Subependymal / diagnosis. Lateral Ventricles. Neurocytoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Nucl Med. 1998 Jun;12 (3):161-4 [9673719.001]
  • [Cites] NMR Biomed. 1989 Dec;2(5-6):196-200 [2561957.001]
  • [Cites] Radiology. 1984 Nov;153(2):435-42 [6333046.001]
  • [Cites] Radiology. 1982 Apr;143(1):97-101 [7063750.001]
  • [Cites] Br J Radiol. 1983 Jun;56(666):425-6 [6850230.001]
  • [Cites] AJR Am J Roentgenol. 1990 Aug;155(2):365-72 [2115270.001]
  • [Cites] AJR Am J Roentgenol. 1995 Nov;165(5):1245-50 [7572512.001]
  • [Cites] J Comput Assist Tomogr. 1995 Mar-Apr;19(2):264-7 [7890853.001]
  • [Cites] Neuroradiology. 1993;35(3):185-6 [8459915.001]
  • [Cites] Oncol Rep. 1998 Sep-Oct;5(5):1199-203 [9683835.001]
  • [Cites] Eur J Nucl Med. 1993 Feb;20(2):138-45 [8440270.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Apr;17(4):737-47 [8730195.001]
  • [Cites] J Magn Reson Imaging. 2003 Feb;17(2):256-60 [12541233.001]
  • [Cites] Neurosurgery. 1999 Jul;45(1):183-7; discussion 187 [10414585.001]
  • [Cites] Surg Neurol. 1990 May;33(5):329-35 [2330534.001]
  • [Cites] Int J Oncol. 1997 Aug;11(2):319-24 [21528217.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):583-8 [1885976.001]
  • [Cites] Kaku Igaku. 2000 Jul;37(4):311-8 [10965651.001]
  • [Cites] Neurol Med Chir (Tokyo). 2001 Sep;41(9):431-4; discussion 435 [11593969.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Jan-Feb;11(1):83-91 [2105621.001]
  • [Cites] Radiology. 2004 Mar;230(3):703-8 [14739313.001]
  • [Cites] Neuroradiology. 1983;25(1):11-22 [6856076.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):329-33; discussion 333-4 [10690721.001]
  • [Cites] J Neurooncol. 2003 Jan;61(1):57-67 [12587796.001]
  • [Cites] Br J Radiol. 1980 May;53(629):443-53 [7388277.001]
  • [Cites] Acta Neurochir (Wien). 2002 Feb;144(2):157-63; discussion 163 [11862516.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Sep;16(8):1593-603 [7502961.001]
  • [Cites] J Comput Assist Tomogr. 1994 Jan-Feb;18(1):129-30 [8282862.001]
  • [Cites] Neurosurgery. 1986 Oct;19(4):594-8 [3785597.001]
  • [Cites] Clin Neurol Neurosurg. 1997 Feb;99(1):17-22 [9107462.001]
  • [Cites] Neuroradiology. 1998 Apr;40(4):210-5 [9592789.001]
  • [Cites] J Nucl Med. 1995 Apr;36(4):537-41 [7699438.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] Radiology. 1978 Aug;128(2):417-22 [663252.001]
  • [Cites] Neuroradiology. 1984;26(3):223-8 [6738854.001]
  • (PMID = 15580370.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Thallium Radioisotopes
  •  go-up   go-down


11. Buccoliero AM, Franchi A, Castiglione F, Gheri CF, Mussa F, Giordano F, Genitori L, Taddei GL: Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology; 2009 Feb;29(1):25-30
Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study.
  • Subependymal giant-cell astrocytoma (SEGA) is a rare intra-ventricular low-grade tumor which frequently occurs as a manifestation of tuberous sclerosis complex.
  • In spite of this, in the recently revised WHO classification of the CNS tumors, SEGA has been still included in the group of astrocytomas.
  • We suggest moving it into the group of mixed glio-neuronal tumors under the denomination of subependymal giant cell tumor.
  • [MeSH-major] Astrocytoma / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564101.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Neurofilament Proteins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


12. Kim SH, Lee KG, Kim TS: Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma. Acta Cytol; 2007 May-Jun;51(3):375-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic characteristics of subependymal giant cell astrocytoma in squash smears: morphometric comparisons with gemistocytic astrocytoma and giant cell glioblastoma.
  • OBJECTIVE: To evaluate the squash smear features of subependymal giant cell astrocytoma (SEGA) in comparison with gemistocytic astrocytoma and giant cell glioblastoma.
  • STUDY DESIGN: We compared the squash smear features of 3 cases of SEGA, 9 cases of gemistocytic astrocytoma and 3 cases of giant cell glioblastoma with the morphometric findings.
  • While the gemistocytic astrocytoma had several tumor cells showing a vertically located nucleus, the tumor cells of SEGA showed nuclei oriented mainly in parallel.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology


13. Stavrinou P, Spiliotopoulos A, Patsalas I, Balogiannis I, Karkavelas G, Polyzoidis K, Selviaridis P: Subependymal giant cell astrocytoma with intratumoral hemorrhage in the absence of tuberous sclerosis. J Clin Neurosci; 2008 Jun;15(6):704-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal giant cell astrocytoma with intratumoral hemorrhage in the absence of tuberous sclerosis.
  • Subependymal giant cell astrocytoma (SEGA) is an uncommon tumor that usually occurs in the setting of tuberous sclerosis (TS) syndrome.
  • Although pre-operative CT and MRI findings for the tumor were typical of SEGA, SEGA was not considered in the differential diagnosis because the patient was lacking any symptoms of TS.
  • This is the second report of intraventricular and intratumoral hemorrhage complicating a SEGA and the first case in which these complications occurred in an adult patient in whom there was no previous suspicion of systemic disease.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Hemorrhage / etiology

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395450.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


14. Raju GP, Urion DK, Sahin M: Neonatal subependymal giant cell astrocytoma: new case and review of literature. Pediatr Neurol; 2007 Feb;36(2):128-31
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal subependymal giant cell astrocytoma: new case and review of literature.
  • Subependymal giant cell astrocytomas are one of the three major intracranial lesions found in tuberous sclerosis complex.
  • Subependymal giant cell astrocytomas are typically slow-growing tumors of mixed glioneuronal lineage which can become aggressive and cause obstructive hydrocephalus usually in older children and adolescents.
  • Neonatal subependymal giant cell astrocytomas are extremely rare, and their natural history and prognosis are poorly understood.
  • This report investigates an extremely large neonatal subependymal giant cell astrocytoma which was initially identified in utero at 19 weeks of gestation in a high-risk pregnancy with no family history of tuberous sclerosis complex.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17275668.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


15. Ibrahim I, Young CA, Larner AJ: Fornix damage from solitary subependymal giant cell astrocytoma causing postoperative amnesic syndrome. Br J Hosp Med (Lond); 2009 Aug;70(8):478-9
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fornix damage from solitary subependymal giant cell astrocytoma causing postoperative amnesic syndrome.
  • The amnesic syndrome is characterized by difficulty learning and recalling information, either previously encoded (retro-grade) or newly encountered (anterograde).
  • This article reports the cognitive impairments associated with left fornix damage which became apparent following surgical removal of a solitary subependymal giant cell astrocytoma.
  • [MeSH-major] Amnesia / etiology. Astrocytoma / complications. Fornix, Brain. Postoperative Complications / etiology

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19684542.001).
  • [ISSN] 1750-8460
  • [Journal-full-title] British journal of hospital medicine (London, England : 2005)
  • [ISO-abbreviation] Br J Hosp Med (Lond)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Chen H, Sun XF, Wu JS: [Clinicopathologic study of subependymal giant cell astrocytoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):656-9
Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of subependymal giant cell astrocytoma].
  • OBJECTIVE: To study the clinicopathologic features of subependymal giant cell astrocytoma.
  • METHODS: The clinical and pathologic characteristics of 18 cases of subependymal giant cell astrocytoma were retrospectively analyzed.
  • The tumor often occurred in the lateral ventricles (16/18, 88.9%).
  • Histologically, there were bundles of spindle cells mixed with clusters of gemistocytes and ganglion-like cells.
  • CONCLUSIONS: Subependymal giant cell astrocytoma is a benign brain tumor with distinctive histopathologic features.
  • The tumor typically affects children and young adults.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374208.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Synaptophysin
  •  go-up   go-down


17. Phi JH, Park SH, Chae JH, Hong KH, Park SS, Kang JH, Jun JK, Cho BK, Wang KC, Kim SK: Congenital subependymal giant cell astrocytoma: clinical considerations and expression of radial glial cell markers in giant cells. Childs Nerv Syst; 2008 Dec;24(12):1499-503
MedlinePlus Health Information. consumer health - Fetal Health and Development.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital subependymal giant cell astrocytoma: clinical considerations and expression of radial glial cell markers in giant cells.
  • OBJECTS: Congenital Subependymal giant cell astrocytoma (SEGA), diagnosed in fetal and neonatal period, is extremely rare.
  • We encountered a patient diagnosed as congenital SEGA and report the surgical outcome along with interesting immuno-phenotypes of giant tumor cells.
  • At postnatal 2 months, gross total resection of the tumor was achieved without complications.
  • The patient had been followed up for 1 year without tumor recurrence.
  • [MeSH-major] Astrocytoma / surgery. Cerebral Ventricle Neoplasms / surgery. Fetal Diseases / surgery
  • [MeSH-minor] Carrier Proteins / biosynthesis. Fatty Acid-Binding Protein 7. Female. Fluorescent Antibody Technique / methods. Humans. Infant, Newborn. Intermediate Filament Proteins / biosynthesis. Male. Nerve Tissue Proteins / biosynthesis. Nestin. Pregnancy. Prenatal Diagnosis. SOXB1 Transcription Factors / biosynthesis. Tumor Suppressor Proteins / biosynthesis. Ultrasonography, Prenatal. Vimentin / biosynthesis

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurol. 2007 Feb;36(2):128-31 [17275668.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Oct;6(10):777-88 [16314867.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):742-8 [17464316.001]
  • [Cites] AJR Am J Roentgenol. 2000 Oct;175(4):1067-9 [11000167.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Nov-Dec;11(6):1251-2 [2124070.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):748-50 [7808622.001]
  • [Cites] Neurosurgery. 1984 May;14(5):570-3 [6728164.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Glia. 2004 Oct;48(1):27-35 [15326612.001]
  • [Cites] Neurology. 2005 Apr 26;64(8):1446-9 [15851742.001]
  • [Cites] Pediatr Radiol. 1999 Oct;29(10 ):776-80 [10525787.001]
  • [Cites] J Neurooncol. 2001 May;52(3):217-25 [11519851.001]
  • [Cites] J Neurosci. 2007 May 23;27(21):5546-58 [17522300.001]
  • [Cites] Glia. 2006 Jan 1;53(1):57-66 [16158418.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 May;20(5):907-16 [10369365.001]
  • [Cites] Pediatr Neurosurg. 2002 May;36(5):271-4 [12053047.001]
  • [Cites] Childs Nerv Syst. 1996 Feb;12 (2):121-3 [8674081.001]
  • [Cites] Curr Opin Neurol. 2000 Apr;13(2):115-9 [10987566.001]
  • (PMID = 18629509.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / FABP7 protein, human; 0 / Fatty Acid-Binding Protein 7; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / Vimentin
  •  go-up   go-down


18. Ess KC, Kamp CA, Tu BP, Gutmann DH: Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex. Neurology; 2005 Apr 26;64(8):1446-9
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex.
  • Children with tuberous sclerosis complex (TSC) harbor developmental brain abnormalities (cortical tubers) and low-grade tumors (subependymal giant cell astrocytomas [SEGAs]).
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Cell Differentiation / genetics. Tuberous Sclerosis / genetics. Tuberous Sclerosis / metabolism
  • [MeSH-minor] Adolescent. Animals. Cell Lineage / genetics. Child. Disease Models, Animal. Female. Gene Expression Profiling. Gene Expression Regulation, Developmental / genetics. Genetic Markers / genetics. Humans. Infant. Male. Mice. Mice, Knockout. Nerve Tissue Proteins / genetics. Neurons / metabolism. Stem Cells / metabolism. Tumor Suppressor Proteins / genetics


19. Ragel BT, Osborn AG, Whang K, Townsend JJ, Jensen RL, Couldwell WT: Subependymomas: an analysis of clinical and imaging features. Neurosurgery; 2006 May;58(5):881-90; discussion 881-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymomas: an analysis of clinical and imaging features.
  • OBJECTIVE: Subependymomas are slow-growing, benign tumors usually found incidentally in the fourth ventricle at autopsy.
  • We review clinical, histological, and contemporary radiographic presentations of 16 subependymomas, including 2 intraparenchymal tumors.
  • METHODS: We retrospectively evaluated eight patients with pathologically proven subependymomas.
  • Imaging was also available on eight outside subependymoma cases reviewed by our radiology department.
  • RESULTS: Twelve of these subependymomas were intraventricular, one was in the posterior fossa, two were intraparenchymal, and one was an intramedullary spinal cord tumor.
  • Among our eight patients who underwent gross total resection with no adjuvant therapy, no recurrences have been noted on follow-up magnetic resonance imaging.
  • CONCLUSION: Subependymomas are rare, representing only 0.51% of all central nervous system tumors operated on during an 8-year period at the University of Utah.
  • Clinical symptoms were associated with tumor location: intracranial masses caused headaches, seizures, and neurological complaints, and spinal cord locations resulted in neurological deficit.
  • The authors review the clinical presentation, management, and contemporary radiographic appearance of this rare tumor.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Glioma, Subependymal / diagnosis. Glioma, Subependymal / surgery. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639322.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Takei H, Adesina AM, Powell SZ: Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex. Neuropathology; 2009 Apr;29(2):181-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex.
  • Subependymal giant cell astrocytoma (SEGA) is a benign, slowly growing tumor typically occurring in the setting of tuberous sclerosis complex (TSC).
  • Histologically, it was composed of interlacing bundles of spindle-shaped tumor cells with thin delicate processes admixed with relatively large pleomorphic cells with abundant glassy eosinophilic cytoplasm, as seen in a SEGA.
  • Immunohistochemically, GFAP, S-100 protein, and neuron specific enolase were positive, and synaptophysin labeled a few tumor cells.
  • Also noted were rare isolated MM cells within the tumor (i.e., tumor-to-tumor metastasis).
  • The histopathological differential diagnosis was limited and included giant cell ependymoma and, much less likely, giant cell glioblastoma and pleomorphic xanthoastrocytoma.
  • Tumor metastasis to an occult SEGA is extremely rare.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Aged. Autopsy. Brain / pathology. Brain / physiopathology. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Melanoma / pathology. Melanoma / physiopathology. Melanoma / secondary. Neoplasm Metastasis. Phosphopyruvate Hydratase / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673443.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


21. Dapena-Sevilla I, Drake-Rodríguez P, Gutiérrez-Ortiz C, Bolívar G, Castejón M, Teus-Guezala MA: [Band atrophy of the optic disc secondary to ventricular subependymoma compression]. Arch Soc Esp Oftalmol; 2007 Sep;82(9):567-9
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Band atrophy of the optic disc secondary to ventricular subependymoma compression].
  • [Transliterated title] Atrofia de disco óptico en banda secundaria a compresión por subependimoma ventricular.
  • Craniotomy and tumor resection were performed.
  • The biopsy revealed a subependymoma of the temporal horn of the left ventricular system.
  • Subependymomas are infrequent and benign tumors that are typically associated with the ventricular system.
  • [MeSH-major] Cerebral Ventricle Neoplasms / complications. Glioma, Subependymal / complications. Optic Atrophy / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846949.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


22. Işik U, Dinçer A, Sav A, Ozek MM: Basal ganglia location of subependymal giant cell astrocytomas in two infants. Pediatr Neurol; 2010 Feb;42(2):157-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal ganglia location of subependymal giant cell astrocytomas in two infants.
  • Subependymal giant cell astrocytomas are benign tumors that constitute one of the primary features of tuberous sclerosis.
  • Two infants with tuberous sclerosis had very unusual subependymal giant cell astrocytomas, confirmed on biopsy in one of the infants.
  • Biopsy of the basal ganglia lesion in that case suggested subependymal giant cell astrocytoma.
  • In infants, subependymal giant cell astrocytomas can present with unusual morphology and may feature diffuse basal ganglia involvement and severe calcification.
  • [MeSH-major] Astrocytoma / pathology. Basal Ganglia / pathology. Brain Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20117758.001).
  • [ISSN] 1873-5150
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ech-Cherif El Kettani N, Salaheddine T, El Quessar A, El Kharras A, El Hassani MR, Chakir N, Boukhrissi N, Benameur M, Jiddane M: [Neuro-imaging of tuberous sclerosis]. J Radiol; 2006 Feb;87(2 Pt 1):109-13
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis is a phakomatosis with central nervous system manifestations characterized by 4 lesions detectable on neuro-imaging: tubers, white matter abnormalities, subependymal nodules and subependymal astrocytomas.
  • The first three are benign lesions composed of by identical cytological lesions varying only in size and location.
  • At CT, enhancement of subependymal nodules is usually considered as evidence of transformation to subependymal giant cell astrocytoma.

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484932.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Ichikawa T, Wakisaka A, Daido S, Takao S, Tamiya T, Date I, Koizumi S, Niida Y: A case of solitary subependymal giant cell astrocytoma: two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism. J Mol Diagn; 2005 Oct;7(4):544-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of solitary subependymal giant cell astrocytoma: two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism.
  • Subependymal giant cell astrocytoma (SEGA) is a unique brain tumor arising in tuberous sclerosis complex (TSC), an autosomal dominant inherited phacomatosis.
  • Here, we report a 20-year-old woman with a brain tumor.
  • Molecular analysis of the tumor revealed loss of heterozygosity and allelic mutation (5228G>A, R1743Q) of TSC2.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Mosaicism. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 1996 Aug;59(2):400-6 [8755927.001]
  • [Cites] Am J Hum Genet. 1999 Jun;64(6):1632-7 [10330349.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1188-93 [9067291.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • [Cites] Am J Hum Genet. 1998 Apr;62(4):810-5 [9529362.001]
  • [Cites] Hum Mutat. 1998;12(6):408-16 [9829910.001]
  • [Cites] J Child Neurol. 1998 Dec;13(12):624-8 [9881533.001]
  • [Cites] N Engl J Med. 1999 Mar 4;340(9):703-7 [10053179.001]
  • [Cites] Hum Mutat. 1999;14(5):412-22 [10533067.001]
  • [Cites] J Med Genet. 2000 Jan;37(1):55-7 [10633137.001]
  • [Cites] Eur J Radiol. 2000 Jan;33(1):55-8 [10674791.001]
  • [Cites] Neurogenetics. 1998 Aug;1(4):267-72 [10732801.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6085-90 [10823953.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):127-9 [10863238.001]
  • [Cites] Am J Hum Genet. 2001 Sep;69(3):493-503 [11468687.001]
  • [Cites] Pediatr Neurosurg. 2002 May;36(5):271-4 [12053047.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 May;42(5):224-7 [12064158.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Dec;43(12):616-8 [14723270.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):812-6 [14871804.001]
  • [Cites] J Neurosurg. 1979 Jan;50(1):106-9 [758371.001]
  • [Cites] Childs Nerv Syst. 1989 Feb;5(1):43-4 [2702677.001]
  • [Cites] Neurosurgery. 1991 Jun;28(6):864-8 [2067610.001]
  • [Cites] J Child Neurol. 1992 Apr;7(2):221-4 [1573244.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Am J Forensic Med Pathol. 1995 Mar;16(1):30-7 [7771379.001]
  • [Cites] Am J Hum Genet. 1999 Apr;64(4):986-92 [10090883.001]
  • [Cites] Am J Hum Genet. 1999 May;64(5):1305-15 [10205261.001]
  • [Cites] Hum Mol Genet. 1996 Feb;5(2):215-21 [8824877.001]
  • (PMID = 16237225.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Other-IDs] NLM/ PMC1888498
  •  go-up   go-down


25. de Ribaupierre S, Dorfmüller G, Bulteau C, Fohlen M, Pinard JM, Chiron C, Delalande O: Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate? Neurosurgery; 2007 Jan;60(1):83-89; discussion 89-90
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: when should we operate?
  • OBJECTIVE: A small percentage of tuberous sclerosis patients will develop a subependymal giant-cell astrocytoma.
  • RESULTS: The results from our own population, as well as from other published pediatric series (15 series), indicate that subependymal giant-cell astrocytomas have a good prognosis when a macroscopically total resection has been performed.
  • CONCLUSION: We think that any lesion fulfilling the criteria for a subependymal giant-cell astrocytoma as previously described in the literature (lesion around the foramen of Monro, greater than 5 mm, with incomplete calcifications) should be removed as soon as clear evidence of growth has been confirmed.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Tuberous Sclerosis / surgery


26. Takata K, Gasparetto EL, Leite Cda C, Lucato LT, Reed UC, Matushita H, Aguiar PH, Rosemberg S: [Subependymal giant cell astrocytoma in patients with tuberous sclerosis: magnetic resonance imaging findings in ten cases]. Arq Neuropsiquiatr; 2007 Jun;65(2A):313-6
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Subependymal giant cell astrocytoma in patients with tuberous sclerosis: magnetic resonance imaging findings in ten cases].
  • [Transliterated title] Astrocitoma subependimário de células gigantes em pacientes com esclerose tuberosa: achados em ressonância magnética de dez casos.
  • OBJECTIVE: To report the magnetic resonance imaging (MRI) findings in 10 patients with subependimal giant cell astrocytoma (SGCA) and tuberous sclerosis (TS).
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Ventricles / pathology. Tuberous Sclerosis / pathology


27. Cai R, Di X: Combined intra- and extra-endoscopic techniques for aggressive resection of subependymal giant cell astrocytomas. World Neurosurg; 2010 Jun;73(6):713-8
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined intra- and extra-endoscopic techniques for aggressive resection of subependymal giant cell astrocytomas.
  • We report two cases of combined intra-/extra-axial endoscopic procedures--intraventricular solid tumor resection for subependymal giant cell astrocytoma.
  • METHODS: In 2007, two patients with subependymal giant cell astrocytoma with a long history of tuberous sclerosis underwent solely endoscopic, minimally invasive intraventricular tumor resection.
  • Pathologic diagnoses were subependymal giant cell astrocytoma.
  • EMIN is a completive, safe procedure for intraventricular subependymal giant cell astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Cerebral Ventricle Neoplasms / surgery. Endoscopy / methods. Frontal Lobe / surgery. Lateral Ventricles / surgery. Neurosurgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20934162.001).
  • [ISSN] 1878-8769
  • [Journal-full-title] World neurosurgery
  • [ISO-abbreviation] World Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Jozwiak J, Kotulska K, Grajkowska W, Jozwiak S, Zalewski W, Oldak M, Lojek M, Rainko K, Maksym R, Lazarczyk M, Skopinski P, Wlodarski P: Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas. Brain Dev; 2007 Jun;29(5):273-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas.
  • Tuberous sclerosis (TS), autosomal dominant disorder manifested by the formation of usually benign tumors in the brain, heart, kidneys and skin, results from an inactivating mutation in one of two tumor suppressor genes TSC1 or TSC2.
  • In order to test this hypothesis we evaluated samples of four subependymal giant cell astrocytomas (SEGAs), brain tumors developing in the progress of TS.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / physiopathology. Brain Neoplasms / complications. Brain Neoplasms / physiopathology. Signal Transduction / physiology. Tuberous Sclerosis / etiology. Tuberous Sclerosis / physiopathology. Up-Regulation / physiology. Wnt Proteins / physiology


29. Orakcioglu B, Schramm P, Kohlhof P, Aschoff A, Unterberg A, Halatsch ME: Characteristics of thoracolumbar intramedullary subependymomas. J Neurosurg Spine; 2009 Jan;10(1):54-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of thoracolumbar intramedullary subependymomas.
  • OBJECT: Thoracolumbar intraspinal subependymomas are very rare intramedullary low-grade tumors.
  • The authors report on the clinical and morphological features of 2 cases of thoracolumbar intraspinal subependymomas and provide midterm follow-up data.
  • METHODS: The clinical and radiological profiles of 2 patients with progressive spinal cord dysfunction due to thoracolumbar intraspinal subependymomas were retrospectively studied and compared with previously reported cases.
  • RESULTS: Patients with intraspinal subependymomas initially presented with back pain and long-tract signs.
  • On follow-up (at 58 and 18 months, respectively), no tumor recurrence was observed.
  • CONCLUSIONS: Symptomatic thoracolumbar intraspinal subependymomas with a distinct appearance on MR imaging are amenable to complete excision with favorable neurological outcome.
  • In this study no tumor recurrence was observed at midterm follow-up in either patient, neither of whom underwent adjuvant therapy.
  • [MeSH-major] Glioma, Subependymal / pathology. Glioma, Subependymal / surgery. Magnetic Resonance Imaging. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19119934.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Clarke MJ, Foy AB, Wetjen N, Raffel C: Imaging characteristics and growth of subependymal giant cell astrocytomas. Neurosurg Focus; 2006;20(1):E5
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging characteristics and growth of subependymal giant cell astrocytomas.
  • OBJECT: Subependymal giant cell astrocytomas (SEGAs) are a common manifestation of tuberous sclerosis (TS).
  • Differentiating SEGAs from subependymal nodules (SENs) before obstruction occurs may improve the morbidity associated with these tumors.
  • Resection was recommended for symptomatic and neuroimaging evidence of hydrocephalus (41%), tumor growth without evidence of hydrocephalus (33%), and for poorly controlled seizures (25%).
  • The mean diameter of the tumors at the time of resection was 1.9 cm (range 0.3-4 cm), and no tumor recurred.
  • Tumor growth and contrast enhancement are the most common signs of progression on neuroimages, and may be seen prior to the development of obstructive hydrocephalus.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459995.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Rushing EJ, Cooper PB, Quezado M, Begnami M, Crespo A, Smirniotopoulos JG, Ecklund J, Olsen C, Santi M: Subependymoma revisited: clinicopathological evaluation of 83 cases. J Neurooncol; 2007 Dec;85(3):297-305
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymoma revisited: clinicopathological evaluation of 83 cases.
  • OBJECT: Subependymomas are rare ependymal neoplasms.
  • To date, a large clinicopathologic study of these benign neoplasms treated with modern neurosurgical techniques has not been reported.
  • METHODS: Eighty-three cases of subependymoma were retrieved from the files of the Armed Forces Institute of Pathology.
  • Eighteen-percent (15/83) of subependymomas exhibited a mixed histologic pattern; that is, subependymoma together with another glial tumor.
  • The most common mixture (13/15) was subependymoma and ependymoma.
  • All patients were without evidence of disease at the last follow-up: alive (n = 28) or dead (n = 8).
  • Subependymomas do not appear to be associated with NF2 mutations.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Glioma, Subependymal / pathology. Infratentorial Neoplasms / pathology. Mixed Tumor, Malignant / pathology

  • Genetic Alliance. consumer health - Subependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 1995 Nov-Dec;16(10):2121-9 [8585504.001]
  • [Cites] J Comput Assist Tomogr. 1995 Jul-Aug;19(4):518-26 [7622676.001]
  • [Cites] AJR Am J Roentgenol. 1995 Nov;165(5):1245-50 [7572512.001]
  • [Cites] J Neurosurg. 1994 Jun;80(6):1108-11 [8189269.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):227-87 [14752523.001]
  • [Cites] J Neurosurg. 1983 Dec;59(6):1088-91 [6631507.001]
  • [Cites] Neurosurgery. 2006 May;58(5):881-90; discussion 881-90 [16639322.001]
  • [Cites] Arch Pathol Lab Med. 1999 Apr;123(4):306-9 [10320142.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):25-8 [15803371.001]
  • [Cites] Mod Pathol. 2005 Jul;18(7):991-7 [15731777.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):583-8 [1885976.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jan 1;108(1):84 [9973931.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Jan-Feb;11(1):83-91 [2105621.001]
  • [Cites] Pathol Int. 2003 Mar;53(3):169-73 [12608898.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):627-32 [10433955.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):741-5 [1407461.001]
  • [Cites] J Neurooncol. 2003 Jan;61(1):57-67 [12587796.001]
  • [Cites] Arch Pathol Lab Med. 1999 Oct;123(10):873 [10506435.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):496-505 [9488304.001]
  • [Cites] J Neurosurg. 1978 Nov;49(5):689-96 [712391.001]
  • [Cites] Neurosurgery. 1986 Oct;19(4):594-8 [3785597.001]
  • [Cites] Clin Neurol Neurosurg. 1997 Feb;99(1):17-22 [9107462.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 May;11(3):567-74 [2349896.001]
  • [Cites] J Neurosurg. 1985 Apr;62(4):508-12 [3973720.001]
  • (PMID = 17569000.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Takei H, Florez L, Bhattacharjee MB: Cytologic features of subependymal giant cell astrocytom: a review of 7 cases. Acta Cytol; 2008 Jul-Aug;52(4):445-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of subependymal giant cell astrocytom: a review of 7 cases.
  • OBJECTIVE: To describe the cytologic features of subependymal giant cell astrocytoma (SEGA) on smears and analyze cytomorphologic parameters that may help in reaching the diagnosis of SEGA.
  • CONCLUSION: The cytologic features of SEGA are highly characteristic and thus are of great use in supporting a diagnosis of SEGA and in excluding mimics, primarily gemistocytic astrocytoma and ependymoma.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Lateral Ventricles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18702362.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Arvanitis LD, Koukoulis GK, Kanavaros P: The expression of the O-linked N-acetylglucosamine containing epitope H in the gemistocytic, pilocytic and subependymal giant cell astrocytomas. Oncol Rep; 2009 Sep;22(3):521-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of the O-linked N-acetylglucosamine containing epitope H in the gemistocytic, pilocytic and subependymal giant cell astrocytomas.
  • In normal human brains the epitope H is present mostly to a minority of fibrous astrocytes, whereas it is greatly up-regulated in reactive astrocytes and is increased in well differentiated fibrillary astrocytomas compared to anaplastic astrocytomas and glioblastomas.
  • In this study the expression of the epitope H was investigated in thirty cases of gemistocytic (WHO grade II), pilocytic (WHO grade I), and subependymal giant cell (WHO grade I) astrocytomas using the mAbH with the indirect immunoperoxidase method.
  • The ten cases of gemistocytic astrocytomas revealed an overall high expression pattern.
  • The ten cases of pilocytic astrocytomas revealed a biphasic pattern of epitope H expression.
  • The dense tumor areas composed of elongated pilocytic cells revealed high expression of the epitope H.
  • The loose cystic tumor areas composed of stellate cells revealed low expression of the epitope H.
  • The ten cases of subependynal giant cell astrocytomas occurring in tuberous sclerosis revealed an overall high expression pattern.
  • This study shows that there is high expression of the epitope H in gemistocytic, pilocytic and subependymal giant cell astrocytomas.
  • Collectively considering, the present and our previous data, it appears that there is a spectrum of the expression levels of the epitope H ranging from the high expression in the reactive astrocytes and low grade astrocytomas to the low/null expression in the normal astrocytes and glioblastomas.
  • [MeSH-major] Acetylglucosamine / analysis. Astrocytoma / chemistry. Brain Neoplasms / chemistry. Epitopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639198.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Epitopes; V956696549 / Acetylglucosamine
  •  go-up   go-down


34. Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Duyndam DA, Zonnenberg BA, Prokop M: Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol; 2009 Jun;16(6):691-6
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature.
  • BACKGROUND AND PURPOSE: To investigate the prevalence of subependymal giant cell ependymomas (SEGA) in patients with tuberous sclerosis complex (TSC).
  • We included all 214 TSC-patients who had received a contrast-enhanced computed tomography (CT) scan of the brain.
  • Average maximum tumor size was 11.4 mm (range, 4-29 mm).
  • No association between tumor size and patient age was detected.
  • Meta-analysis of reported prevalence and our current study showed that studies using radiological evidence to diagnose SEGA gave a higher pooled estimate of the prevalence of SEGA in TSC (0.16; 95% CI: 0.12, 0.21) than studies using mainly histopathological evidence of SEGA (0.09; 95% CI: 0.07, 0.12).
  • [MeSH-major] Astrocytoma / epidemiology. Brain Neoplasms / epidemiology. Tuberous Sclerosis / epidemiology


35. Rath TJ, Sundgren PC, Brahma B, Lieberman AP, Chandler WF, Gebarski SS: Massive symptomatic subependymoma of the lateral ventricles: case report and review of the literature. Neuroradiology; 2005 Mar;47(3):183-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive symptomatic subependymoma of the lateral ventricles: case report and review of the literature.
  • Subependymomas are benign intraventricular tumors with an indolent growth pattern, which are usually asymptomatic, and most commonly occur in the fourth and lateral ventricles.
  • When symptomatic, subependymomas often obstruct critical portions of the cerebrospinal fluid (CSF) pathway, causing hydrocephalus, and range from 3 cm to 5 cm in size.
  • We report a case of an unusually massive subependymoma of the lateral ventricles treated with subtotal resection, ventriculoperitoneal shunt, and post-surgical radiation.
  • The clinical course, radiographic and pathologic characteristics of this massive intraventricular subependymoma are discussed, as well as the differential diagnosis of lateral ventricular masses and a review of the literature concerning subependymomas.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Glioma, Subependymal / diagnosis

  • Genetic Alliance. consumer health - Subependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiographics. 2002 Nov-Dec;22(6):1473-505 [12432118.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Nov-Dec;16(10):2121-9 [8585504.001]
  • [Cites] AJR Am J Roentgenol. 1990 Aug;155(2):365-72 [2115270.001]
  • [Cites] AJR Am J Roentgenol. 1995 Nov;165(5):1245-50 [7572512.001]
  • [Cites] J Comput Assist Tomogr. 1995 Mar-Apr;19(2):264-7 [7890853.001]
  • [Cites] Neuroradiology. 1993;35(3):185-6 [8459915.001]
  • [Cites] J Neuropathol Exp Neurol. 1978 Mar-Apr;37(2):103-18 [632843.001]
  • [Cites] Cancer. 1974 Dec;34(6):1992-2008 [4434329.001]
  • [Cites] J Neurooncol. 2003 May;62(3):315-20 [12777084.001]
  • [Cites] Surg Neurol. 1990 May;33(5):329-35 [2330534.001]
  • [Cites] Acta Neuropathol. 1977 Nov 28;40(3):279-82 [203160.001]
  • [Cites] Arch Pathol Lab Med. 1999 Apr;123(4):306-9 [10320142.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):583-8 [1885976.001]
  • [Cites] Acta Neurochir (Wien). 1989;98 (1-2):25-31 [2662707.001]
  • [Cites] J Neurooncol. 2003 Jan;61(1):57-67 [12587796.001]
  • [Cites] J Neurosurg. 1978 Nov;49(5):689-96 [712391.001]
  • [Cites] Neurosurg Rev. 2000 Jun;23(2):98-103 [10926103.001]
  • [Cites] Neurosurgery. 1986 Oct;19(4):594-8 [3785597.001]
  • [Cites] Neuropathol Appl Neurobiol. 1984 Jan-Feb;10(1):63-75 [6738805.001]
  • [Cites] Clin Neurol Neurosurg. 1997 Feb;99(1):17-22 [9107462.001]
  • [Cites] J Neurosurg. 1985 Apr;62(4):508-12 [3973720.001]
  • [Cites] Acta Neurochir (Wien). 1989;96(1-2):15-25 [2929389.001]
  • (PMID = 15702322.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 23
  •  go-up   go-down


36. Dashti SR, Robinson S, Rodgers M, Cohen AR: Pineal region giant cell astrocytoma associated with tuberous sclerosis: case report. J Neurosurg; 2005 Apr;102(3 Suppl):322-5
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pineal region giant cell astrocytoma associated with tuberous sclerosis: case report.
  • Tuberous sclerosis complex is a genetic disorder characterized by the development of hamartomas in multiple organs including the brain, skin, eye, kidney, and heart.
  • Cortical tubers and subependymal nodules are the characteristic intracranial lesions of tuberous sclerosis.
  • Subependymal giant cell astrocytomas, typically located adjacent to the foramen of Monro, can enlarge and cause symptomatic ventricular obstruction.
  • The authors describe the case of a 3-year-old boy with a history of tuberous sclerosis and retinal lesions who presented with an enlarging enhancing pineal region mass.
  • Pathological examination showed a giant cell astrocytoma.
  • To the authors' knowledge, this is the first reported case of tuberous sclerosis associated with a giant cell astrocytoma of the pineal region.
  • [MeSH-major] Astrocytoma / complications. Astrocytoma / surgery. Pinealoma / complications. Pinealoma / surgery. Tuberous Sclerosis / complications

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881760.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Levine NB, Collins J, Franz DN, Crone KR: Gradual formation of an operative corridor by balloon dilation for resection of subependymal giant cell astrocytomas in children with tuberous sclerosis: specialized minimal access technique of balloon dilation. Minim Invasive Neurosurg; 2006 Oct;49(5):317-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gradual formation of an operative corridor by balloon dilation for resection of subependymal giant cell astrocytomas in children with tuberous sclerosis: specialized minimal access technique of balloon dilation.
  • BACKGROUND: Major sources of morbidity and mortality in patients with tuberous sclerosis who develop subependymal giant cell astrocytomas (SEGAs) relate to tumor growth and resultant hydrocephalus.
  • We describe a modification of a specialized minimal access resection technique in which an operative corridor is formed with balloon dilation over the course of a week prior to tumor resection.
  • METHODS: Three patients with tuberous sclerosis who had an enlarging SEGA and concomitant hydrocephalus underwent surgical resection with this modified technique.
  • A frontal craniotomy was performed and the optimal trajectory for tumor resection was confirmed by image guidance.
  • One week after the first operation, the balloon was deflated and removed, and the patient underwent tumor resection via the newly formed operative corridor.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Catheterization / methods. Craniotomy / methods. Minimally Invasive Surgical Procedures / methods. Tuberous Sclerosis / surgery


38. Tyburczy ME, Kotulska K, Pokarowski P, Mieczkowski J, Kucharska J, Grajkowska W, Roszkowski M, Jozwiak S, Kaminska B: Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. Am J Pathol; 2010 Apr;176(4):1878-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
  • Subependymal giant cell astrocytomas (SEGAs) are rare brain tumors associated with tuberous sclerosis complex (TSC), a disease caused by mutations in TSC1 or TSC2, resulting in enhancement of mammalian target of rapamycin (mTOR) activity, dysregulation of cell growth, and tumorigenesis.
  • Of the genes differentially expressed in TSC, 11 were validated by real-time PCR on independent tumor samples and 3 SEGA-derived cultures.
  • [MeSH-major] Astrocytoma / metabolism. Gene Expression Regulation, Neoplastic. Giant Cells / cytology. TOR Serine-Threonine Kinases / metabolism. Tuberous Sclerosis / metabolism

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):865-70 [10639171.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14866-70 [10611304.001]
  • [Cites] J Cell Biol. 2000 Jun 12;149(6):1193-206 [10851017.001]
  • [Cites] J Child Neurol. 2000 Oct;15(10):652-9 [11063078.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13227-32 [11078525.001]
  • [Cites] Oncogene. 2000 Dec 14;19(54):6306-16 [11175345.001]
  • [Cites] J Neurooncol. 2001 May;52(3):217-25 [11519851.001]
  • [Cites] Genome Biol. 2001;2(8):RESEARCH0032 [11532216.001]
  • [Cites] Acta Med Okayama. 2002 Feb;56(1):31-4 [11873942.001]
  • [Cites] Mol Cell Neurosci. 2002 Dec;21(4):561-74 [12504590.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Nat Cell Biol. 2003 Jun;5(6):578-81 [12771962.001]
  • [Cites] Nat Biotechnol. 2003 Jul;21(7):818-21 [12794640.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3469-75 [12960139.001]
  • [Cites] Oncogene. 2003 Oct 23;22(48):7617-27 [14576824.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):73-9 [14695321.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):13-9 [14999150.001]
  • [Cites] Mol Endocrinol. 2004 Apr;18(4):995-1003 [14726486.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] World J Gastroenterol. 2004 May 15;10(10):1466-70 [15133855.001]
  • [Cites] Nat Biotechnol. 2004 Jun;22(6):656-8; author reply 658 [15175677.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] J Ment Defic Res. 1985 Dec;29 ( Pt 4):383-9 [4093964.001]
  • [Cites] Neurochem Res. 1986 Jun;11(6):825-38 [3736769.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Int J Cancer. 1995 Jan 3;60(1):73-81 [7814155.001]
  • [Cites] Nature. 1995 Feb 23;373(6516):721-4 [7854459.001]
  • [Cites] Acta Neuropathol. 1995;90(4):387-99 [8546029.001]
  • [Cites] J Biol Chem. 1996 Jan 12;271(2):719-25 [8557678.001]
  • [Cites] J Cell Biol. 1997 Apr 21;137(2):481-92 [9128257.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1432-7 [9465032.001]
  • [Cites] Arch Neurol. 1998 Mar;55(3):379-84 [9520012.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):704-13 [9858593.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 7;326(1):218-27 [15567174.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1385-91 [15668896.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):606-11 [15701847.001]
  • [Cites] Histopathology. 2005 Mar;46(3):256-69 [15720411.001]
  • [Cites] Gene Expr. 2005;12(2):123-36 [15892453.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 17;102(20):7215-20 [15883373.001]
  • [Cites] Prostate. 2005 Sep 1;64(4):332-40 [15754346.001]
  • [Cites] J Neurosci. 2006 Jan 18;26(3):757-62 [16421295.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):653-8 [16423993.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] J Biol Chem. 2006 Mar 31;281(13):8313-6 [16464865.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):1970-82 [16609006.001]
  • [Cites] Curr Biol. 2006 May 23;16(10):958-70 [16713952.001]
  • [Cites] Exp Cell Res. 2007 Feb 15;313(4):719-31 [17182035.001]
  • [Cites] Cell Signal. 2007 Aug;19(8):1621-32 [17553668.001]
  • [Cites] Neuron. 2007 Jul 5;55(1):87-102 [17610819.001]
  • [Cites] Neuromolecular Med. 2007;9(2):117-27 [17627032.001]
  • [Cites] J Neurochem. 2007 Aug;102(3):887-99 [17630985.001]
  • [Cites] Mol Cancer Res. 2007 Oct;5(10):1001-14 [17951401.001]
  • [Cites] Neurosurg Rev. 2008 Jan;31(1):83-9; discussion 89-90 [17917751.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):73-9 [18177819.001]
  • [Cites] Cancer. 2008 Apr 1;112(7):1575-84 [18260157.001]
  • [Cites] Mol Cancer Res. 2008 Jun;6(6):1017-28 [18567805.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):2065-72 [18697201.001]
  • [Cites] Biochem Soc Trans. 2009 Feb;37(Pt 1):259-64 [19143643.001]
  • [Cites] Neuropathology. 2009 Feb;29(1):25-30 [18564101.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17786-92 [10748068.001]
  • (PMID = 20133820.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 63231-63-0 / RNA; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC2843477
  •  go-up   go-down


39. Birca A, Mercier C, Major P: Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. J Neurosurg Pediatr; 2010 Oct;6(4):381-4
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex.
  • Tuberous sclerosis complex (TSC) is associated with the potential development of benign hamartomas, including subependymal giant cell astrocytomas (SEGAs).
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Sirolimus / administration & dosage. Tuberous Sclerosis / complications


40. O'Callaghan FJ, Martyn CN, Renowden S, Noakes M, Presdee D, Osborne JP: Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study. Arch Dis Child; 2008 Sep;93(9):751-4
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal nodules, giant cell astrocytomas and the tuberous sclerosis complex: a population-based study.
  • OBJECTIVES:. (1) In a population-based study of tuberous sclerosis (TSC), to identify the number of patients presenting with symptomatic giant cell astrocytomas (GCAs);.
  • (2) within a subset of this population, to identify the number who would be diagnosed with GCAs on predetermined radiological criteria.
  • Thirty-nine of these had subependymal nodules, of whom 24 (59%) had at least one (maximum 11) that showed enhancement with gadolinium.
  • CONCLUSIONS: In this study, the proportion of patients with TSC who had a history of symptomatic GCA was 5.6%.
  • In the subset without such a history, who underwent imaging, the number diagnosed as having a GCA on radiological criteria was much higher (59% gadolinium enhancement and 17% >1 cm in size).
  • Screening for GCAs (performing scans on asymptomatic patients with TSC) would therefore identify large numbers of patients who had not presented with symptoms.
  • This finding leads us to recommend that screening should not be undertaken.
  • [MeSH-major] Astrocytoma / epidemiology. Brain Neoplasms / epidemiology. Tuberous Sclerosis / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Cross-Sectional Studies. Female. Humans. Intracranial Hypertension / etiology. Intracranial Hypertension / surgery. Magnetic Resonance Imaging. Male. Mental Disorders / etiology. Tomography, X-Ray Computed. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dis Child. 2009 Jan;94(1):75-6 [19103791.001]
  • (PMID = 18456692.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins
  •  go-up   go-down


41. Akamatsu Y, Utsunomiya A, Suzuki S, Endo T, Suzuki I, Nishimura S, Ezura M, Suzuki H, Uenohara H, Tominaga T: Subependymoma in the lateral ventricle manifesting as intraventricular hemorrhage. Neurol Med Chir (Tokyo); 2010;50(11):1020-3
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymoma in the lateral ventricle manifesting as intraventricular hemorrhage.
  • A 32-year-old man presented with subependymoma in the lateral ventricle causing intraventricular hemorrhage and manifesting as severe headache and disturbance of consciousness.
  • Magnetic resonance imaging at 5 weeks after admission showed a tumor arising from the septum pellucidum or the floor of the right lateral ventricle, appearing as a mixed-intensity solid tumor, which was partially enhanced following gadolinium administration.
  • The tumor had arisen from the septum pellucidum and was totally removed via an interhemispheric anterior transcallosal approach.
  • Histological examination found typical subependymoma, with little vascularity.
  • Since subependymomas are quite benign and show poor vascularity, intraventricular or subarachnoid hemorrhages are very rare, but do occasionally occur.
  • [MeSH-major] Cerebral Hemorrhage / etiology. Cerebral Ventricle Neoplasms / complications. Cerebral Ventricle Neoplasms / diagnosis. Glioma, Subependymal / complications. Glioma, Subependymal / diagnosis. Lateral Ventricles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21123990.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ, Avezaat CJ, Kros JM: Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer; 2006 Jan 15;106(2):388-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
  • Furthermore, in many investigations, myxopapillary ependymomas and subependymomas were included and may have confounded results, because those tumors should be considered clinicopathologic entities distinct from the other ependymomas.
  • METHODS: In this retrospective study, the influence of the histologic subtype of ependymoma and of individual histologic features on the outcome of 69 patients with ependymomas was investigated.
  • Myxopapillary ependymomas, subependymomas, and ependymomas with spinal localizations were excluded from the analysis.
  • Neither tumor localization (either infratentorial or supratentorial), patient age, nor gender affected survival.
  • The survival of patients who underwent complete tumor resection differed significantly from that of patients who underwent partial resection.
  • CONCLUSIONS: The results of the univariate analysis indicated that, for patients with intracranial ependymoma, nuclear atypia, the mitotic index, and the MIB-1 LI significantly influenced survival.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Ependymoma / mortality. Ependymoma / pathology. Glioma, Subependymal / mortality. Glioma, Subependymal / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342252.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / MIB-1 antibody
  •  go-up   go-down


43. Yu T, Zeng C, Zhao JZ: [Intracranial subependymoma: clinical features and surgical management of 22 cases]. Zhonghua Yi Xue Za Zhi; 2010 Mar 23;90(11):756-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracranial subependymoma: clinical features and surgical management of 22 cases].
  • OBJECTIVE: To study the clinical features, neuro-radiology and treatment of intracranial subependymomas.
  • METHODS: A total of 22 subependymomas were reviewed with regards to clinical presentation, neuro-imaging features, treatment, histopathological features and long-term follow-up.
  • One tumor was located in temporal lobe, mesencephalon, thalamus and pons.
  • CONCLUSION: Intracranial subependymoma is a rare benign tumor.
  • The prognosis is excellent and there is a rare tumor recurrence.
  • [MeSH-major] Brain Neoplasms. Glioma, Subependymal

  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20627021.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


44. Chittiboina P, Zhang S, Bao J, Vannemreddy P, Guthikonda B: Subependymoma at the foramen of Monro presenting with intermittent hydrocephalus: case report and review of the literature. J La State Med Soc; 2010 Jul-Aug;162(4):214-7
MedlinePlus Health Information. consumer health - Hydrocephalus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymoma at the foramen of Monro presenting with intermittent hydrocephalus: case report and review of the literature.
  • Subependymomas are benign neoplasms, accounting for 0.5 % of all central nervous system tumors.
  • However, patients may be symptomatic with the symptoms depending on location of the tumor.
  • Since subependymomas typically arise from the ventricular wall, obstruction of cerebrospinal fluid is a major cause of onset symptoms.
  • We present a rare case report of a subependymoma at the foramen of Monro presenting with intermittent hydrocephalus.
  • The patient's tumor was asymptomatic for many years.
  • Our report illustrates a case of intermittent hydrocephalus due to a sessile subependymoma.
  • Even though our patient presented with a histologically benign ventricular tumor, she demonstrated rapidly worsening symptoms that culminated in herniation.
  • By presenting our case report, we hope to draw attention to this rare but potentially life-threatening presentation of subependymoma.
  • Once diagnosed, we recommend early tumor removal and restoration of normal cerebrospinal fluid (CSF) pathways for these intraventricular tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cerebral Ventricles. Glioma, Subependymal / diagnosis. Hydrocephalus / etiology
  • [MeSH-minor] Disease Progression. Female. Headache / etiology. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hydrocephalus.
  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882814.001).
  • [ISSN] 0024-6921
  • [Journal-full-title] The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
  • [ISO-abbreviation] J La State Med Soc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Limaïem F, Bellil SB, Bellil K, Chelly I, Jemel H, Haouet S, Khaldi M, Zitouna M, Kchir N: Subependymomas: a clinicopathological study of 6 symptomatic cases. Pathologica; 2008 Oct;100(5):401-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymomas: a clinicopathological study of 6 symptomatic cases.
  • BACKGROUND: Subependymomas are rare, slow-growing, ependymal neoplasms that commonly occur in the fourth or lateral ventricles.
  • OBJECTIVE AND DESIGN: A retrospective study of 6 histologically proven subependymomas was undertaken to analyse their clinicopathological characteristics.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Glioma, Subependymal / pathology. Lateral Ventricles / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cerebral Ventriculography. Child. Female. Fourth Ventricle / chemistry. Fourth Ventricle / pathology. Fourth Ventricle / radiography. Glial Fibrillary Acidic Protein / analysis. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. Retrospective Studies. Tomography, X-Ray Computed. Vimentin / analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253599.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Neoplasm Proteins; 0 / Vimentin
  •  go-up   go-down


46. Koutourousiou M, Georgakoulias N, Kontogeorgos G, Seretis A: Subependymomas of the lateral ventricle: tumor recurrence correlated with increased Ki-67 labeling index. Neurol India; 2009 Mar-Apr;57(2):191-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymomas of the lateral ventricle: tumor recurrence correlated with increased Ki-67 labeling index.
  • Subependymomas of the lateral ventricles are rare tumors.
  • We present two patients with subependymomas of the lateral ventricle, who underwent gross total resection of the tumor via transcallosal approach.
  • The patient, with increased Ki-67 labeling index had recurrence of tumor two years after the initial operation.
  • [MeSH-major] Cerebral Ventricle Neoplasms / metabolism. Glioma, Subependymal / metabolism. Ki-67 Antigen / metabolism. Lateral Ventricles / pathology. Neoplasm Recurrence, Local / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19439853.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


47. Carrasco R, Pascual JM, Navas M, Fraga J, Manzanares-Soler R, Sola RG: Spontaneous acute hemorrhage within a subependymoma of the lateral ventricle: successful emergent surgical removal through a frontal transcortical approach. Neurocirugia (Astur); 2010 Dec;21(6):478-83
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous acute hemorrhage within a subependymoma of the lateral ventricle: successful emergent surgical removal through a frontal transcortical approach.
  • INTRODUCTION. Subependymomas are benign neoplasms intimately related to the ventricular system which only exceptionally associate hemorrhagic events.
  • We present neuroradiological and pathological evidences of intratumoral hemorrhage within a single case of subependymoma operated on at our institution.
  • Pathological diagnosis was consistent with subependymoma displaying areas of microhemorrhage.
  • CONCLUSIONS. A spontaneous hemorrhagic event within an asymptomatic lateral ventricle subependymoma can result in a surgical emergence as a consequence of sudden obstruction of cerebrospinal fluid pathways.
  • [MeSH-major] Cerebral Hemorrhage / surgery. Cerebral Ventricle Neoplasms. Glioma, Subependymal. Lateral Ventricles. Neurosurgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21165545.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


48. Jabri HE, Dababo MA, Alkhani AM: Subependymoma of the spine. Neurosciences (Riyadh); 2010 Apr;15(2):126-8
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymoma of the spine.
  • Subependymoma is a rare benign CNS tumor (WHO grade I).
  • The common sites of origin for this type of tumor are the lateral and the fourth ventricles.
  • Radiological features of intramedullary subependymoma can mimic more common and more aggressive tumor types.
  • We report a case of a 61-year-old male who presented with a 3-year history of low back pain, associated with right lower limb progressive weakness and sensory numbness.
  • Clinical presentation, radiological, and pathological studies of this case of subependymoma are presented.
  • The incidence of spinal subependymoma was also discussed in light of a literature review.
  • [MeSH-major] Glioma, Subependymal / diagnosis. Spinal Cord Neoplasms / diagnosis. Spine / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672503.001).
  • [ISSN] 1319-6138
  • [Journal-full-title] Neurosciences (Riyadh, Saudi Arabia)
  • [ISO-abbreviation] Neurosciences (Riyadh)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


49. Zenmyo M, Ishido Y, Terahara M, Yamamoto T, Tanimoto A, Komiya S, Ijiri K: Intramedullary subependymoma of the cervical spinal cord: a case report with immunohistochemical study. Int J Neurosci; 2010 Oct;120(10):676-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramedullary subependymoma of the cervical spinal cord: a case report with immunohistochemical study.
  • Spinal subependymomas, which have a relatively benign nature, are very rare tumors.
  • It is difficult to distinguish spinal subependymomas from other intramedullary spinal tumors based on neuroradiological findings.
  • A case of cervical intramedullary subependymoma in a 63-year-old female is reported.
  • Enhancement in the small part of the tumor was observed on a T1-weighted MRI with gadolinium administration.
  • The tumor occupied the left side of the spinal cord, and was totally removed through a laminoplasty of C2.
  • [MeSH-major] Ependyma / pathology. Glioma, Subependymal / pathology. Spinal Cord / pathology. Spinal Cord Neoplasms / pathology

  • Genetic Alliance. consumer health - Subependymoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20942580.001).
  • [ISSN] 1563-5279
  • [Journal-full-title] The International journal of neuroscience
  • [ISO-abbreviation] Int. J. Neurosci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Piao Y, Lu L, de Groot J: AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol; 2009 Jun;11(3):260-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix.
  • High-grade gliomas release excitotoxic concentrations of glutamate, which has been shown to enhance tumor proliferation and migration. alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) glutamate receptors are abundantly expressed at the invading edge of glioblastoma specimens, suggesting they may play an important biologic role in tumor invasion.
  • In this study, we examined potential mechanisms by which AMPA receptor (AMPAR) expression and stimulation promote glioma cell migration and invasion.
  • Overexpression of GluR1, the most abundant AMPAR subunit in gliomas, positively correlated with glioma cell adhesion to type I and type IV collagen, which was decreased in cells with knockdown of GluR1 and with blocking antibodies to beta1 integrin.
  • Cells overexpressing GluR1 had increased colocalization of actin and paxillin at FAs and, in several glioma cell lines, significantly increased invasion in an in vitro Matrigel transwell assay.
  • Likewise, in an intracranial xenograft model, overexpression of GluR1 led to perivascular and subependymal glioma cell invasion similar to patterns of tumor dissemination described in human glioblastoma.
  • Together, these results suggest that AMPARs may link signals from the ECM to sites of FA, where signal integration promotes tumor invasion.
  • [MeSH-major] Antigens, CD29 / metabolism. Extracellular Matrix / metabolism. Glioma / pathology. Neoplasm Invasiveness / genetics. Receptors, AMPA / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Adhesion / genetics. Cell Line, Tumor. Cell Movement / genetics. Collagen / metabolism. Female. Flow Cytometry. Fluorescent Antibody Technique. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Gene Expression. Humans. Immunoprecipitation. Mice. Mice, Nude. Signal Transduction / physiology. Transfection. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res Mol Brain Res. 2000 Dec 28;85(1-2):41-52 [11146105.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):637-44 [10980705.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16248-56 [11340084.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6372-7 [11331750.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5688-91 [11479198.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1010-5 [11533703.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):7875-81 [11751905.001]
  • [Cites] Curr Opin Cell Biol. 2002 Apr;14(2):214-20 [11891121.001]
  • [Cites] Biochemistry. 2002 Jun 11;41(23):7275-82 [12044158.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Aug;3(8):586-99 [12154370.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] Nat Med. 2002 Sep;8(9):971-8 [12172541.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] J Cell Sci. 2002 Nov 15;115(Pt 22):4285-91 [12376560.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):91-100 [12635172.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8030-41 [14585964.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5353-68 [15169899.001]
  • [Cites] J Mol Endocrinol. 2004 Jun;32(3):859-68 [15171717.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28715-23 [15102844.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Oct;4(5):803-21 [15485315.001]
  • [Cites] J Biol Chem. 1987 Dec 25;262(36):17536-42 [2961737.001]
  • [Cites] Eur J Biochem. 1991 Jul 1;199(1):25-33 [1906002.001]
  • [Cites] Science. 1993 Apr 2;260(5104):95-7 [8096653.001]
  • [Cites] J Neurosci. 1993 Sep;13(9):3904-15 [8103555.001]
  • [Cites] J Cell Sci. 1996 Mar;109 ( Pt 3):643-52 [8907709.001]
  • [Cites] Immunol Lett. 1996 Dec;54(2-3):189-93 [9052876.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2435-47 [9703890.001]
  • [Cites] Front Biosci. 1999 Feb 15;4:D188-99 [9989953.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4383-91 [10485487.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1029-40 [10515226.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):8197-207 [15611137.001]
  • [Cites] J Neurochem. 2005 Jul;94(2):531-46 [16000124.001]
  • [Cites] Nat Methods. 2004 Nov;1(2):163-7 [16144086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13479-83 [16157875.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1379-87 [16251422.001]
  • [Cites] J Neurosci. 2006 Jan 4;26(1):223-32 [16399691.001]
  • [Cites] J Neurosci. 2006 Mar 1;26(9):2458-66 [16510724.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 12;343(3):910-6 [16564504.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):127-36 [16533879.001]
  • [Cites] Glia. 2006 Jun;53(8):799-808 [16541395.001]
  • [Cites] Pathol Int. 2006 May;56(5):262-71 [16669875.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3233-7 [16740741.001]
  • [Cites] Mol Biol Cell. 2007 Jan;18(1):253-64 [17093062.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9463-71 [17909056.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93 [17971532.001]
  • [Cites] Neurology. 2008 Mar 4;70(10):779-87 [18316689.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):206-20 [18328425.001]
  • [Cites] J Neurooncol. 2008 Jun;88(2):121-33 [18317690.001]
  • [Cites] J Neurosci. 2000 Nov 1;20(21):7932-40 [11050113.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):166-79 [10579921.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10767-77 [10594060.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):326-33 [10659021.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):105-17 [11322830.001]
  • (PMID = 18957620.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Receptors, AMPA; 0 / glutamate receptor ionotropic, AMPA 1; 9007-34-5 / Collagen; EC 2.7.10.2 / Focal Adhesion Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC2718970
  •  go-up   go-down


51. Maekawa M, Fujisawa H, Iwayama Y, Tamase A, Toyota T, Osumi N, Yoshikawa T: Giant subependymoma developed in a patient with aniridia: analyses of PAX6 and tumor-relevant genes. Brain Pathol; 2010 Nov;20(6):1033-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant subependymoma developed in a patient with aniridia: analyses of PAX6 and tumor-relevant genes.
  • We observed an unusually large subependymoma in a female patient with congenital aniridia.
  • To analyze the genetic mechanisms of tumorigenesis, we first examined the paired box 6 (PAX6) gene using both tumor tissue and peripheral lymphocytes.
  • Tumor suppressor activity has been proposed for PAX6 in gliomas, in addition to its well-known role in the eye development.
  • The subependymoma had an additional de novo deletion spanning from the intron 4 to intron 6 of PAX6, although we could not completely determine whether these two deletions are on the same chromosome or not.
  • We also examined other potentially relevant tumor suppressor genes: PTEN, TP53 and SOX2.
  • Collectively, we speculate that the defect in PAX6 may have contributed to the extremely large size of the subependymoma, due to a loss of tumor suppressor activity in glial cell lineage.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Eye Proteins / genetics. Homeodomain Proteins / genetics. Paired Box Transcription Factors / genetics. Repressor Proteins / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Aniridia.
  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors; Brain Pathology © 2010 International Society of Neuropathology.
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17306-13 [10747901.001]
  • [Cites] Stem Cells. 2009 Jan;27(1):40-8 [18948646.001]
  • [Cites] Tohoku J Exp Med. 2001 Mar;193(3):163-74 [11315763.001]
  • [Cites] Hum Genet. 2001 Jul;109(1):11-8 [11479730.001]
  • [Cites] Nucleic Acids Res. 2001 Oct 1;29(19):4070-8 [11574690.001]
  • [Cites] Schizophr Res. 2001 Dec 1;52(3):171-9 [11705711.001]
  • [Cites] Hum Mutat. 2003 Feb;21(2):138-45 [12552561.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Cancer. 1974 Dec;34(6):1992-2008 [4434329.001]
  • [Cites] Acta Neuropathol. 1977 Nov 28;40(3):279-82 [203160.001]
  • [Cites] J Neurosurg. 1978 Nov;49(5):689-96 [712391.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:6-16 [6953802.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):583-8 [1885976.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):463-71 [7951315.001]
  • [Cites] J Biol Chem. 1997 Feb 7;272(6):3430-6 [9013587.001]
  • [Cites] Dan Med Bull. 1997 Nov;44(5):535-9 [9408738.001]
  • [Cites] Int J Dev Biol. 2004;48(8-9):819-27 [15558474.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):223-9 [15735909.001]
  • [Cites] Neurosurgery. 2006 May;58(5):881-90; discussion 881-90 [16639322.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2683-710 [17974913.001]
  • [Cites] J Neurosci. 2008 Apr 30;28(18):4604-12 [18448636.001]
  • [Cites] J Cell Biochem. 2008 Aug 15;104(6):2298-309 [18561328.001]
  • [Cites] Brain Pathol. 2008 Oct;18(4):469-73 [18397339.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1166-74 [18776908.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):179-85 [10861471.001]
  • (PMID = 20500513.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Eye Proteins; 0 / Homeodomain Proteins; 0 / PAX6 protein; 0 / Paired Box Transcription Factors; 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2991767
  •  go-up   go-down


52. White JB, Miller GM, Layton KF, Krauss WE: Nonenhancing tumors of the spinal cord. J Neurosurg Spine; 2007 Oct;7(4):403-7
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Enhancement of pathological entities in the central nervous system is a common finding when the blood-brain barrier has been compromised.
  • In the brain, the presence or absence of gadolinium enhancement is often an indicator of tumor invasiveness and/or grade.
  • In the spinal cord, however, contrast enhancement has been shown in all tumor types, regardless of grade.
  • Histologically, a majority of tumors were astrocytomas (eight low-grade and two high-grade lesions); one tumor was a subependymoma.
  • The absence of enhancement does not imply the absence of tumor.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / radiography. Glioma, Subependymal / pathology. Glioma, Subependymal / radiography. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / radiography

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933314.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


53. Kurian KM, Jones DT, Marsden F, Openshaw SW, Pearson DM, Ichimura K, Collins VP: Genome-wide analysis of subependymomas shows underlying chromosomal copy number changes involving chromosomes 6, 7, 8 and 14 in a proportion of cases. Brain Pathol; 2008 Oct;18(4):469-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide analysis of subependymomas shows underlying chromosomal copy number changes involving chromosomes 6, 7, 8 and 14 in a proportion of cases.
  • Subependymomas (SE) are slow-growing brain tumors that tend to occur within the ventricles of middle-aged and elderly adults.
  • The World Health Organization classifies these tumors within the ependymoma group.
  • Previous limited analysis of this tumor type had not revealed significant underlying cytogenetic abnormalities.
  • The observation that five of 12 cases examined (42%) at 0.97-Mb resolution showed chromosomal copy number abnormalities is a novel finding in this tumor type.
  • [MeSH-major] Cerebral Ventricle Neoplasms / genetics. Chromosomes, Human / genetics. Gene Dosage / genetics. Genetic Predisposition to Disease / genetics. Glioma, Subependymal / genetics. Monosomy. Trisomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]
  • [Cites] Oncogene. 2006 Feb 23;25(8):1261-71 [16205629.001]
  • [Cites] J Neurooncol. 2007 Dec;85(3):297-305 [17569000.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Oct 1;122(1):63-4 [11104036.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Mar;30(3):310-5 [11170291.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25959-69 [11356838.001]
  • [Cites] Am J Hum Genet. 2001 Aug;69(2):341-50 [11443539.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Sep;62(9):927-35 [14533782.001]
  • [Cites] Mol Cell Biol. 2004 May;24(9):3747-56 [15082770.001]
  • [Cites] Cancer. 1974 Dec;34(6):1992-2008 [4434329.001]
  • [Cites] Acta Neuropathol. 1977 Nov 28;40(3):279-82 [203160.001]
  • [Cites] J Neurosurg. 1978 Nov;49(5):689-96 [712391.001]
  • [Cites] J Neurosurg. 1979 May;50(5):655-9 [571009.001]
  • [Cites] J Neurosurg. 1985 Apr;62(4):508-12 [3973720.001]
  • [Cites] Acta Neurochir (Wien). 1989;96(1-2):15-25 [2929389.001]
  • [Cites] Int J Cancer. 1989 Oct 15;44(4):579-81 [2793229.001]
  • [Cites] Br J Neurosurg. 1987;1(3):317-21 [3268127.001]
  • [Cites] Cytogenet Cell Genet. 1989;52(3-4):136-8 [2630185.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):583-8 [1885976.001]
  • [Cites] Childs Nerv Syst. 1991 Aug;7(4):177-82 [1933913.001]
  • [Cites] J Biol Chem. 1992 Aug 5;267(22):16000-6 [1639825.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Apr;6(4):199-205 [7685621.001]
  • [Cites] Neurosurgery. 1993 Jul;33(1):145-50 [8355833.001]
  • [Cites] Oncogene. 1994 Jan;9(1):89-96 [8302607.001]
  • [Cites] J Neurosurg. 1994 Jun;80(6):1108-11 [8189269.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1065-72 [8806696.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):251-7 [8869051.001]
  • [Cites] Eur Urol. 1998;34(5):419-25 [9803005.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jan 1;108(1):84 [9973931.001]
  • [Cites] Arch Pathol Lab Med. 1999 Apr;123(4):306-9 [10320142.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):627-32 [10433955.001]
  • [Cites] J Neuropathol Exp Neurol. 1954 Jan;13(1):30-49 [13118373.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):181-93 [15770670.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • (PMID = 18397339.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC2659379
  •  go-up   go-down


54. Schramm J, Blümcke I, Ostertag CB, Schlegel U, Simon M, Lutterbach J: Low-grade gliomas -- current concepts. Zentralbl Neurochir; 2006 May;67(2):55-66
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade gliomas -- current concepts.
  • Diffuse astrocytomas, oligodendrogliomas, and oligoastrocytomas (mixed gliomas) WHO grade II, pleomorphic xanthoastrocytomas (PXAs), pilocytic astrocytomas, and subependymal giant cell astrocytomas (SEGAs) are often referred to as low-grade gliomas.
  • WHO grade II astrocytomas, oligodendrogliomas, and mixed gliomas are characterized by their infiltrative growth, frequent tumor recurrence and a more than 50 % risk for malignant progression.
  • In contrast, pilocytic astrocytomas and SEGAs are circumscribed tumors amenable to a (radio)surgical cure.
  • There are few universally accepted guidelines for the treatment of low-grade gliomas.
  • In this review, three neurosurgeons, a neurologist, a neuropathologist, and a radiation oncologist discuss some of the difficult issues surrounding the diagnosis and treatment of low-grade gliomas from their individual points of view (i. e., classification and neuropathology, MR imaging, stereotactic biopsy, microsurgery, interstitial radiotherapy/brachytherapy, radiotherapy, wait and see strategy).
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Neurosurgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673237.001).
  • [ISSN] 0044-4251
  • [Journal-full-title] Zentralblatt für Neurochirurgie
  • [ISO-abbreviation] Zentralbl. Neurochir.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


55. Jang WY, Lee JK, Lee JH, Kim JH, Kim SH, Lee KH, Lee MC: Intramedullary subependymoma of the thoracic spinal cord. J Clin Neurosci; 2009 Jun;16(6):851-3
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramedullary subependymoma of the thoracic spinal cord.
  • We report a rare case of a thoracic intramedullary subependymoma in a 37-year-old woman.
  • The patient developed a monoparesis of the right leg after a subtotal resection of the tumor.
  • During the 30 months of follow-up the neurological deficit improved and the patient remained symptom free without progression of the remnant tumor.
  • A complete resection of the tumor is usually curative with improved function.
  • In patients with poor delineation between the tumor and the spinal cord, subtotal removal and close follow-up should be considered.
  • [MeSH-major] Glioma, Subependymal / pathology. Spinal Cord / pathology. Spinal Cord Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19297162.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


56. Holveck A, Grand S, Boini S, Kirchin M, Le Bas JF, Dietemann JL, Bracard S, Kremer S: Dynamic susceptibility contrast-enhanced MRI evaluation of cerebral intraventricular tumors: preliminary results. J Neuroradiol; 2010 Dec;37(5):269-75
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 28 patients with intraventricular tumors (five meningiomas, five papillomas, three ependymomas, four subependymomas, seven central neurocytomas, two subependymal giant cell astrocytomas and two metastases) underwent conventional and dynamic susceptibility contrast-enhanced MRI.
  • Cerebral blood volume (CBV) maps were obtained and the relative CBV (rCBV) calculated for each tumor.
  • RESULTS: Intraventricular tumors presented with three different patterns of vascularization: highly vascularized tumors (mean rCBV(max)>3), including papillomas, meningiomas and renal carcinoma metastases; poorly vascularized tumors (mean rCBV(max)<2), including ependymomas and subependymomas; and intermediately vascularized tumors (mean rCBV(max)>2 but<3), including central neurocytomas and lung metastases.
  • There was a significant difference between the highly vascularized (papillomas, meningiomas) and poorly vascularized (subependymomas) tumors.
  • In cases of suspected meningioma, papilloma or neurocytoma, low rCBV values (<3) point to a diagnosis of neurocytoma rather than either of the other tumor types.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Magnetic Resonance Imaging / methods. Meningioma / pathology. Neurocytoma / pathology. Papilloma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20435349.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


57. Fujisawa H, Hasegawa M, Ueno M: Clinical features and management of five patients with supratentorial subependymoma. J Clin Neurosci; 2010 Feb;17(2):201-4
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and management of five patients with supratentorial subependymoma.
  • Subependymoma is a rare low-grade glioma of the central nervous system that is often asymptomatic and discovered incidentally.
  • Of the three symptomatic patients, one presented with sudden loss of consciousness despite having only a small tumor, while in contrast, another patient showed only gradual memory disturbance despite having a very large tumor (90 mm diameter).
  • We concluded that as surgery is the only curative treatment for subependymoma, and even a small tumor can present with sudden deterioration, we recommend early and total resection.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricles / pathology. Glioma, Subependymal / diagnosis. Lateral Ventricles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20036555.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


58. Koral K, Kedzierski RM, Gimi B, Gomez A, Rollins NK: Subependymoma of the cerebellopontine angle and prepontine cistern in a 15-year-old adolescent boy. AJNR Am J Neuroradiol; 2008 Jan;29(1):190-1
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymoma of the cerebellopontine angle and prepontine cistern in a 15-year-old adolescent boy.
  • SUMMARY: A case of cerebellopontine angle and prepontine cistern subependymoma in a 15-year-old adolescent boy is presented with a review of the literature.
  • Apparent diffusion coefficient values for subependymoma are reported.
  • Differential considerations for the unusual location of this rare tumor are discussed.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Cerebellopontine Angle / pathology. Cerebellopontine Angle / radiography. Glioma, Subependymal / diagnosis. Magnetic Resonance Imaging / methods. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925361.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


59. Romoli S, Abbruzzese A, Castagna M, Becherini F, Parenti G: Unusual exophytic subependymoma in the bulbo-cerebellar angle. Case report. J Neurosurg Sci; 2007 Jun;51(2):81-4
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual exophytic subependymoma in the bulbo-cerebellar angle. Case report.
  • Subependymoma was first described by Scheinker in 1945; it frequently occurs in the ventricles and rarely in the spinal canal representing 0.7% of all central nervous system tumours.
  • We report a case of subependymoma with a completely exophytic growth from the foramen of Luscka: only a similar one has been described in the literature but with a lesser cysternal involvement.
  • Neuroradiological and anatomopathological features of subependymoma are discussed.
  • [MeSH-major] Cerebellopontine Angle / pathology. Cerebral Ventricle Neoplasms / pathology. Fourth Ventricle / pathology. Glioma, Subependymal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571040.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


60. Ohmura T, Tsugu H, Iwaasa M, Utsunomiya H, Fukushima T, Inoue T: Subependymoma with prominent rosenthal fiber formation: case report. Neurol Med Chir (Tokyo); 2010;50(10):933-5
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymoma with prominent rosenthal fiber formation: case report.
  • A 62-year-old woman presented with a rare case of subependymoma associated with prominent Rosenthal fibers located in the left lateral ventricle manifesting as right hemiparesis and mild motor aphasia.
  • The tumor was well demarcated and consisted of clusters of round nuclei embedded in an abundant gliofibrillary matrix with some microcysts and prominent Rosenthal fibers.
  • Immunohistochemically, the tumor stained positively for glial fibrillary acidic protein and negatively for synaptophysin.
  • This case of subependymoma containing Rosenthal fiber formation is very unusual.
  • [MeSH-major] Astrocytes / pathology. Extracellular Matrix / pathology. Glioma, Subependymal / pathology. Lateral Ventricles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21030810.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, Kaminska B, Konarska L: Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res; 2007 Mar 16;1137(1):161-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The efficacy of cannabinoids against high-grade glioma in animal models, mediated by two specific receptors, CB1 and CB2, raised promises for targeted treatment of the most frequent and malignant primary brain tumors.
  • Most glioblastomas expressed very high levels of CB2 receptors and the expression correlated with tumor grade.
  • Interestingly, some benign pediatric astrocytic tumors, such as subependymal giant cell astrocytoma (SEGA), which may occasionally cause mortality owing to progressive growth, also displayed high CB2 immunoreactivity.
  • Our results suggest that the CB2 receptor expression depends primarily on the histopathological origin of the brain tumor cells and differentiation state, reflecting the tumor grade.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Astrocytoma / metabolism. Child. Glioblastoma / metabolism. Histocompatibility Antigens / metabolism. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239827.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Histocompatibility Antigens; 0 / Receptor, Cannabinoid, CB2
  •  go-up   go-down


62. Osztie E, Hanzély Z, Afra D: Lateral ventricle gliomas and central neurocytomas in adults diagnosis and perspectives. Eur J Radiol; 2009 Jan;69(1):67-73
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lateral ventricle gliomas and central neurocytomas in adults diagnosis and perspectives.
  • Neuroimaging data of lateral ventricle gliomas and central neurocytomas diagnosed in one institution were reviewed and compared to the corresponding literature data.
  • Thirteen subependymomas were hypodense, mostly without enhancement, but occasionally mild or moderate enhancement was noted.
  • Eight subependymal giant cell astrocytomas also displayed hypodense, rarely hyperdense or mixed imaging characteristics, and always showed significant degree of contrast enhancement.
  • Nineteen central neurocytomas showed hypo- or mixed density, but mostly mild to moderate enhancement.
  • Ependymomas and anaplastic astrocytomas and glioblastomas followed the characteristics of the similar extraventricular ones.
  • In our series low-grade astrocytomas, WHO I-II [Louis DN, Ohgaki H, Wiestler OD, Canevee WK.
  • WHO classification of tumours of the central nervous system.
  • Our data support those of previous studies in that MRI has been found to be superior to CT for a more precise imaging of lateral ventricle gliomas.
  • Survival data were available in 65 cases, which have confirmed a favourable outcome in most of the patients with subependymoma, subependymal giant cell astrocytoma, central neurocytomas or pilocytic astrocytoma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods. Neurocytoma / diagnosis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023315.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


63. Gibson SE, Zeng WF, Weil RJ, Prayson RA: Aurora B kinase expression in ependymal neoplasms. Appl Immunohistochem Mol Morphol; 2008 May;16(3):274-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aurora B kinase expression in ependymal neoplasms.
  • Overexpression of Aurora B kinase, which regulates cell progression through mitosis and cytokinesis, has been shown to be associated with higher-grade tumors and shortened survival in astrocytomas.
  • Aurora B expression was evaluated by immunohistochemistry in 32 ependymomas, 10 anaplastic ependymomas, 16 myxopapillary ependymomas, and 9 subependymomas.
  • Aurora B expression was identified in 20 (62.5%) ependymomas, 5 (50%) anaplastic ependymomas, 1 (6.3%) myxopapillary ependymoma, and no subependymomas.
  • The association between Aurora B expression and World Health Organization grade II/III tumors was statistically significant (P<0.0001).
  • Aurora B expression was not associated with patient age, sex, tumor location, tumor recurrence, or death from tumor.
  • In contrast to astrocytomas, elevated Aurora B expression in higher-grade ependymomas does not seem to correlate with clinical course, although it may be a potential target of Aurora kinase inhibitors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301241.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


64. Tadros R, Tonkin A: Bilateral bulbar palsy and postural hypotension following surgery for fourth ventricle subependymoma. J Clin Neurosci; 2009 Dec;16(12):1646-8
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral bulbar palsy and postural hypotension following surgery for fourth ventricle subependymoma.
  • We report a 54-year-old man who developed bilateral bulbar palsy and severe postural hypotension following resection of a fourth ventricle subependymoma.
  • [MeSH-minor] Cerebral Ventricle Neoplasms / pathology. Cerebral Ventricle Neoplasms / surgery. Glioma, Subependymal / pathology. Glioma, Subependymal / surgery. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766493.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


65. Yadav RK, Agarwal S, Saini J, Sharma NK: Imaging appearance of subependymoma: a rare tumor of the cord. Indian J Cancer; 2008 Jan-Mar;45(1):33-5
Genetic Alliance. consumer health - Subependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging appearance of subependymoma: a rare tumor of the cord.
  • Subependymoma of the cord are rare tumors with very few cases described in the literature.
  • They are biologically benign with low proliferative index, hence postoperative prognosis is very good.
  • We present a case of a 42-year-old male patient with an intramedullary Subependymoma located within the central canal of thoracic region cord.
  • On imaging with T1-weighted and T2-weighted sequences it mimicked syringohydromyelia, however, on heavily T2-weighted images the tumor located within the central canal could be delineated.
  • The tumor was excised with complete recovery.
  • [MeSH-major] Glioma, Subependymal / diagnosis. Spinal Cord Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453739.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


66. Boada M, Gómez E, Puig J, Pedraza S: [Intraventricular fibrous tumor: a case report]. Radiologia; 2009 Sep-Oct;51(5):512-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraventricular fibrous tumor: a case report].
  • [Transliterated title] Tumor fibroso intraventricular: a propósito de un caso.
  • Solitary fibrous tumor was first reported in the pleura; however, it has since been reported in many other locations.
  • To our knowledge, only eight cases of intraventricular solitary fibrous tumor have been reported.
  • We describe a case of intraventricular solitary fibrous tumor.The imaging characteristics of intraventricular solitary fibrous tumors are nonspecific; the differential diagnosis should include other tumors that can affect the ventricular system such as meningioma, high grade glioma, metastasis, subependymoma, choroid plexus papilloma, ependymoma, subependymal giant cell astrocytoma, and neurocytoma.
  • At histological study, immunohistochemical techniques allow solitary fibrous tumor to be differentiated from fibrous meningioma and hemangiopericytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646726.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


67. Fisher PG, Tihan T, Goldthwaite PT, Wharam MD, Carson BS, Weingart JD, Repka MX, Cohen KJ, Burger PC: Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer; 2008 Aug;51(2):245-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome analysis of childhood low-grade astrocytomas.
  • BACKGROUND: We aimed to determine the long-term natural history of low-grade astrocytomas (LGA) in children, with respect to pathology, and to evaluate influence of treatment on survival.
  • RESULTS: Two hundred seventy-eight children (160 males; mean age 9.1 years; tumor location: 77 cerebrum, 62 cerebellum, 51 hypothalamic, 30 thalamus, 9 ventricle, 40 brainstem, and 9 spine) were assessed.
  • Among 246 specimens reviewed, diagnoses were 135 pilocytic astrocytoma (PA), 27 diffuse astrocytoma (DA), 75 unclassifiable well-differentiated astrocytoma (NOS), and 9 subependymal giant cell astrocytoma.
  • Reviewed diagnoses were highly associated with OS (P < 0.0001), with 5-year OS for PA 96%, DA 48%, and NOS 86%; these differences remained significant when stratified by location or extent of resection.
  • Among patients with residual tumor after surgery, 5-year PFS was 48% with observation alone (n = 114), no different (P = 0.32) from that achieved with immediate irradiation (n = 86).
  • While tumor location and resection extent affect outcome, pathologic diagnosis when carefully interpreted significantly influences long-term survival.
  • [MeSH-major] Astrocytoma / mortality. Brain Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386785.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Laxton AW, Shannon P, Nag S, Farb RI, Bernstein M: Rapid expansion of a previously asymptomatic subependymoma. Case report. J Neurosurg; 2005 Dec;103(6):1084-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid expansion of a previously asymptomatic subependymoma. Case report.
  • One month after his initial presentation, he was admitted to the hospital with significant tumor expansion and clinical deterioration.
  • Histopathological analysis of this tumor showed central necrosis with associated edema in an otherwise typical and benign-appearing subependymoma.
  • To the authors' knowledge, this is the first reported case of rapid, nonhemorrhagic expansion associated with necrosis in a previously asymptomatic subependymoma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Glioma, Subependymal / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Brain Edema / etiology. Cranial Fossa, Posterior. Craniotomy. Disease Progression. Headache / etiology. Humans. Male. Necrosis. Time Factors

  • Genetic Alliance. consumer health - Subependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381197.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Murai N, Kaneko T: [Case of jugular foramen schwannoma associated with tuberous sclerosis]. No Shinkei Geka; 2007 Oct;35(10):1007-11
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her tuberous sclerosis was diagnosed at the age of 9, when she developed hydrocephalus caused by subependymal giant cell astrocytoma near the foramen of Monro, which was treated by surgical resection and VP shunt placement followed by radiation and chemotherapy.
  • The tumor was partially removed via suboccipital craniotomy and histologically diagnosed as a schwannoma.
  • No tumor regrowth has been observed at 94 months.
  • [MeSH-minor] Adult. Astrocytoma / etiology. Astrocytoma / therapy. Cerebral Ventricle Neoplasms / etiology. Cerebral Ventricle Neoplasms / therapy. Cerebral Ventricles. Female. Humans. Hydrocephalus / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Schwannoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969337.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


70. Tan KB, Magdalene Koh HK, Tan SY: Double immunofluorescence shows coexpression of Bcl-x with GFAP in a variety of glial lesions. J Neurooncol; 2006 Dec;80(3):235-42
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The former included astrocytomas, GBMs, ependymomas, oligodendrogliomas, gangliogliomas, subependymomas and neurocytomas.
  • Expression of Bcl-x closely follows that of GFAP with strong expression in both reactive astrocytes and astrocytomas.
  • There is more focal expression in other gliomas.
  • Double immunolabelling confirms the coexpression of Bcl-x and GFAP in various gliomas and reactive brain conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2005 Jun;58(6):590-4 [15917408.001]
  • [Cites] Oncol Rep. 1999 Mar-Apr;6(2):365-9 [10023006.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5501-7 [7923184.001]
  • [Cites] Am J Dermatopathol. 2004 Jun;26(3):242-7 [15166516.001]
  • [Cites] J Neurol Sci. 1998 Feb 18;155(1):68-75 [9562325.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):169-77 [14996501.001]
  • [Cites] Cell Death Differ. 2003 Jul;10(7):823-32 [12815465.001]
  • [Cites] Acta Neuropathol. 1987;74(2):105-23 [3314309.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):554-9 [9435230.001]
  • [Cites] Cell Tissue Res. 1997 Apr;288(1):59-68 [9042772.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):229-49 [14996506.001]
  • [Cites] Hum Pathol. 1999 Jun;30(6):701-5 [10374780.001]
  • [Cites] Cancer J Sci Am. 1997 Jul-Aug;3(4):230-7 [9263629.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Feb;31(1):62-9 [15634232.001]
  • [Cites] Rocz Akad Med Bialymst. 2004;49 Suppl 1:16-8 [15638361.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):805-14 [9060818.001]
  • [Cites] Brain Res. 1996 Mar 18;712(2):281-6 [8814903.001]
  • (PMID = 16773221.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / bcl-X Protein
  •  go-up   go-down


71. Kidd EA, Mansur DB, Leonard JR, Michalski JM, Simpson JR, Perry A: The efficacy of radiation therapy in the management of grade I astrocytomas. J Neurooncol; 2006 Jan;76(1):55-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of radiation therapy in the management of grade I astrocytomas.
  • INTRODUCTION: The purpose of this study was to analyze the outcome of patients with grade I astrocytomas treated with radiation therapy, specifically looking at the prognostic significance of age, timing of radiation therapy (immediately after surgery or delayed until progression) and tumor location.
  • MATERIALS AND METHODS: The records of patients with grade I astrocytomas treated at Washington University Medical Center between 1982 and 2002 were reviewed.
  • Twenty patients with grade I pilocytic astrocytoma (n=19) or subependymal giant cell astrocytoma (n=1) were treated with radiation therapy with curative intent.
  • Patients who received radiation therapy immediately after biopsy or surgery had a 5-year PFS of 77% versus 50% for patients who received radiation therapy after initial disease progression (P=0.013).
  • All tumor recurrences were local.
  • CONCLUSIONS: While this study reports an excellent overall survival, approximately one third of patients with grade I astrocytomas had progressive disease following radiation therapy.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1979 Jul;44(1):276-80 [455252.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):811-5 [3998829.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):919-27 [3967199.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):171-6 [3392563.001]
  • [Cites] Cancer. 1973 Sep;32(3):646-55 [4199356.001]
  • [Cites] Childs Nerv Syst. 1995 Feb;11(2):89-96 [7758018.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):661-4 [2809719.001]
  • [Cites] Childs Nerv Syst. 1995 Aug;11(8):438-42 [7585678.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10 [11597812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):815-8 [2323970.001]
  • [Cites] Oncology (Williston Park). 1993 Jul;7(7):97-104, 107; discussion 108-11 [8347464.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] Pediatr Neurosurg. 2001 Dec;35(6):311-7 [11786699.001]
  • (PMID = 16132503.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner R: Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival. Mod Pathol; 2009 Dec;22(12):1600-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival.
  • It serves as a substrate for the epidermal growth factor receptor (EGFR), which is frequently amplified in primary gliomas.
  • It is unclear how annexin-1 is expressed in various neuroepithelial tumors, and whether there is any association with tumor malignancy or survival.
  • In the normal human brain, the expression of annexin-1 is limited to ependymal cells and subependymal astrocytes, but is also upregulated in reactive astrocytes.
  • Ependymomas and astrocytomas showed significantly higher mean annexin-1 expression levels in the cytoplasm compared with oligodendrogliomas (both: P<0.0001).
  • In addition, nuclear staining of annexin-1 in oligodendroglial tumor cells was significantly reduced (P=0.0002), which may be used as a diagnostic tool for differentiating between astrocytomas and oligodendrogliomas.
  • Although annexin-1 expression in ependymomas decreased with the grade of malignancy, diffuse astrocytomas showed a significant increase in cytoplasmic annexin-1-positive tumor cells.
  • Thus, annexin-1 upregulation in astrocytomas may contribute to tumor progression and its expression profile is similar to its substrate, EGFR, suggesting a possible regulation thereof.
  • [MeSH-major] Annexin A1 / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Glioma / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytoma / chemistry. Blotting, Western. Cell Nucleus / chemistry. Child. Child, Preschool. Ependymoma / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Logistic Models. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / chemistry. Prognosis. Receptor, Epidermal Growth Factor / analysis. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Time Factors. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767728.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Biomarkers, Tumor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


73. Choi YL, Kim CJ, Matsuo T, Gaetano C, Falconi R, Suh YL, Kim SH, Shin YK, Park SH, Chi JG, Thiele CJ: HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors. J Neurooncol; 2005 May;73(1):19-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten human brains at different developmental stages and 118 cases of nervous system tumor tissues were examined by immunohistochemistry.
  • Twelve related tumor cell lines were also analyzed by northern blotting and immunoblotting.
  • Among tumors, hUlip expression was easily detected in tumor cells undergoing neuronal differentiation such as ganglioneuroblastomas and ganglioneuromas.
  • Furthermore, hUlip immunoreactivity was also found in various brain tumors showing neuronal differentiation: central neurocytomas (6 of 6 cases were positive), medulloblastomas (5/11), atypical teratoid rhabdoid tumor (1/1) and gangliogliomas (4/7).
  • Some astrocytic tumors also showed weak positivity: astrocytomas (1 of 5 cases), anaplastic astrocytomas (2/5), and glioblastomas (3/11).
  • Subependymal giant cell astrocytomas and subependymomas, which are of controversial histogenetic origin, showed strong hUlip immunoreactivity.
  • [MeSH-minor] Astrocytes / cytology. Astrocytes / metabolism. Cell Differentiation / genetics. Cell Differentiation / physiology. Cell Line, Tumor. Female. Gestational Age. Humans. Immunohistochemistry. Male. Neuroblastoma / genetics. Neuroblastoma / metabolism. Neurons / cytology. Neurons / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Neurosci. 1999 Dec;11(12):4226-32 [10594648.001]
  • [Cites] Lab Invest. 1990 Apr;62(4):498-509 [2159086.001]
  • [Cites] Brain Dev. 1998 Mar;20(2):88-94 [9545178.001]
  • [Cites] Brain Res Dev Brain Res. 1997 Sep 20;102(2):305-8 [9352115.001]
  • [Cites] Genetics. 1992 Nov;132(3):675-89 [1468626.001]
  • [Cites] J Neuroophthalmol. 2001 Sep;21(3):164-7 [11725180.001]
  • [Cites] Brain Dev. 1999 Jan;21(1):41-50 [10082252.001]
  • [Cites] Dev Biol. 1985 Sep;111(1):158-70 [3928418.001]
  • [Cites] Annu Rev Neurosci. 1995;18:385-408 [7605067.001]
  • [Cites] Brain Res. 2002 Oct 18;952(2):153-8 [12376175.001]
  • [Cites] J Neurosci. 2003 Apr 1;23(7):2815-23 [12684468.001]
  • [Cites] Neuron. 1994 Oct;13(4):805-11 [7524558.001]
  • [Cites] Lab Invest. 1989 Dec;61(6):635-43 [2557487.001]
  • [Cites] Biol Neonate. 1996;69(4):257-67 [8724654.001]
  • [Cites] Cereb Cortex. 1996 Nov-Dec;6(6):794-806 [8922336.001]
  • [Cites] J Natl Cancer Inst. 1984 Aug;73(2):405-16 [6589432.001]
  • [Cites] Gene. 1996 Nov 21;180(1-2):157-63 [8973361.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):175-82 [10721710.001]
  • [Cites] Hum Genet. 1996 Feb;97(2):240-3 [8566961.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):12195-201 [9115293.001]
  • [Cites] J Neurosci. 1995 Oct;15(10):6757-66 [7472434.001]
  • [Cites] Int J Cancer. 1990 Jun 15;45(6):1079-87 [2161798.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] J Neurosci. 1996 Oct 1;16(19):6197-207 [8815901.001]
  • [Cites] Acta Neuropathol. 1986;70(3-4):320-6 [3020862.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2197-211 [1544125.001]
  • [Cites] J Comp Neurol. 1995 May 8;355(3):369-79 [7636019.001]
  • [Cites] Neuropathol Appl Neurobiol. 1984 Jan-Feb;10(1):63-75 [6738805.001]
  • [Cites] Nature. 1995 Aug 10;376(6540):509-14 [7637782.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):574-80 [9181582.001]
  • [Cites] Neuron. 1993 Aug;11(2):321-31 [8394722.001]
  • [Cites] J Biol Chem. 1995 Oct 20;270(42):24725-31 [7559588.001]
  • (PMID = 15933812.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DPYSL3 protein, human; 0 / Muscle Proteins
  •  go-up   go-down


74. Pollock JM, Whitlow CT, Tan H, Kraft RA, Burdette JH, Maldjian JA: Pulsed arterial spin-labeled MR imaging evaluation of tuberous sclerosis. AJNR Am J Neuroradiol; 2009 Apr;30(4):815-20
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Tuberous sclerosis presents with characteristic cortical hamartomas and subependymal nodules associated with seizures.
  • One patient had a subependymal giant cell astrocytoma with a mean perfusion of 93.5 mL/100 g tissue/min.
  • [MeSH-minor] Adolescent. Astrocytoma / etiology. Astrocytoma / pathology. Brain Diseases / complications. Brain Diseases / pathology. Brain Neoplasms / etiology. Brain Neoplasms / pathology. Child. Child, Preschool. Disease Progression. Hamartoma / complications. Hamartoma / pathology. Humans. Infant. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147711.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB004673
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Spin Labels
  •  go-up   go-down


75. Ariga T, Suetake K, Nakane M, Kubota M, Usuki S, Kawashima I, Yu RK: Glycosphingolipid antigens in neural tumor cell lines and anti-glycosphingolipid antibodies in sera of patients with neural tumors. Neurosignals; 2008;16(2-3):226-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycosphingolipid antigens in neural tumor cell lines and anti-glycosphingolipid antibodies in sera of patients with neural tumors.
  • To characterize biomarkers in neural tumors, we analyzed the acidic lipid fractions of 13 neural tumor cell lines using enzyme-linked immunoabsorbent assay (ELISA) and high-performance thin-layer chromatography (HPTLC) immunostaining.
  • Sulfoglucuronosyl paragloboside (SGPG) was the prominent species with lesser amounts of sulfoglucuronosyl lactosaminyl paragloboside (SGLPG) in these tumor cell lines as assessed by quantitative HPTLC immunostaining.
  • Among the gangliosides surveyed, GD3 and 9-O-acetylated GD3 (OAc-GD3) were expressed in all tumor cell lines.
  • All sera had high titers of antibodies of the IgM isotype against SGPG (titers over 1:3,200), especially in tumors such as meningiomas, germinomas, orbital tumors, glioblastomas, medulloblastomas, and subependymomas.
  • Serum in a patient with subependymomas also had a high anti-SGGL antibody titer of the IgG and IgA types (titers over 12,800).
  • The titer of anti-GD3 antibody was also elevated in patients with subependymomas and medulloblastomas; the latter cases also had a high titer of antibody against OAc-GD3.
  • Our data indicate that certain GSL antigens, especially SGGLs, GD3, and OAc-GD3, are expressed in neural tumor cells and may be considered as tumor-associated antigens that represent important biomarkers for neural tumors.
  • Furthermore, antibody titers in sera of patients with these tumors may be of diagnostic value for monitoring the presence of tumor cells and tumor progression.
  • [MeSH-major] Antibodies, Neoplasm / blood. Antigens, Neoplasm / blood. Glycosphingolipids / physiology. Nervous System Neoplasms / immunology
  • [MeSH-minor] Animals. Biomarkers / blood. Cattle. Cell Line, Tumor. Humans

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18253060.001).
  • [ISSN] 1424-8638
  • [Journal-full-title] Neuro-Signals
  • [ISO-abbreviation] Neurosignals
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 2 RO1 NS26994-33
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Glycosphingolipids
  •  go-up   go-down


76. Henderson MA, Fakiris AJ, Timmerman RD, Worth RM, Lo SS, Witt TC: Gamma knife stereotactic radiosurgery for low-grade astrocytomas. Stereotact Funct Neurosurg; 2009;87(3):161-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife stereotactic radiosurgery for low-grade astrocytomas.
  • Patients with low-grade astrocytoma (LGA; 8 pilocytic astrocytomas, 2 subependymal giant cell astrocytomas, 2 fibrillary astrocytomas) were selected for treatment with gamma knife stereotactic radiosurgery (GKSRS) based on having a demarcated appearance on CT or MRI and the possibility of dose sparing of adjacent eloquent structures.
  • A median dose of 13 Gy was prescribed to the 50% isodose line, which covered the gross tumor.
  • With a median follow-up of 48.2 months, 4-year tumor control and overall survival were 77 and 83%, respectively.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Radiosurgery / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19321969.001).
  • [ISSN] 1423-0372
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


77. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol; 2008 Dec;116(6):597-602
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
  • A total of 221 somatic IDH1 mutations were detected and the highest frequencies occurred in diffuse astrocytomas (68%), oligodendrogliomas (69%), oligoastrocytomas (78%) and secondary glioblastomas (88%).
  • The very high frequency of IDH1 mutations in WHO grade II astrocytic and oligodendroglial gliomas suggests a role in early tumor development.
  • [MeSH-minor] Astrocytoma / genetics. Astrocytoma / pathology. Base Sequence. DNA Mutational Analysis. Disease Progression. Gene Frequency. Glioblastoma / genetics. Glioblastoma / pathology. Glioma / etiology. Glioma / pathology. Humans. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18985363.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  •  go-up   go-down


78. Roma AA, Prayson RA: Expression of cyclo-oxygenase-2 in ependymal tumors. Neuropathology; 2006 Oct;26(5):422-8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclo-oxygenase-2 in ependymal tumors.
  • Up-regulation of cyclo-oxygenase-2 (COX-2), a cytokine-induced enzyme that metabolizes arachidonic acid into prostaglandins, has been described in some brain tumors, including astrocytomas.
  • Little is known about its expression in ependymal neoplasms.
  • The objective of the present study was to assess COX-2 immunostaining of ependymal tumors.
  • Retrospective COX-2 immunohistochemical analysis was conducted on 117 ependymal tumors.
  • The study group (56 men and 44 women, mean age, 30.8 years) was comprised of 48 low-grade ependymomas (WHO grade II), 12 anaplastic ependymomas (WHO grade III), 27 myxopapillary ependymomas (WHO grade I) and 13 subependymomas (WHO grade I).
  • At last known follow-up (range, 12-226 months; mean, 74 months), 52 patients were alive with no evidence of tumor, 16 patients were alive with residual tumor, nine patients died with tumor, one patient died with no tumor and three died with tumor status unknown.
  • Thirty-six (36%) patients had tumors, which demonstrated positive COX-2 staining, including 16/27 (59%) myxopapillary ependymomas, 3/13 (23%) subependymomas, 14/48 (29%) ependymomas and 3/12 (25%) anaplastic ependymomas.
  • Statistically significant COX-2 positive immunostaining was observed in myxopapillary ependymomas versus WHO grade II (P = 0.03) and grade III (P = 0.02) tumors.
  • Increased COX-2 expression in myxopapillary ependymoma as compared to the WHO grade II and II ependymoma was observed.
  • The reason for this apparent increased immunoexpression in these low-grade tumors is uncertain.
  • COX-2 inhibitors may play a role in treatment of the subset of ependymal tumors that demonstrate increased expression.
  • COX-2 staining did not reliably predict tumor behavior.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cyclooxygenase 2 / biosynthesis. Ependymoma / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080719.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


79. Rogers L, Pueschel J, Spetzler R, Shapiro W, Coons S, Thomas T, Speiser B: Is gross-total resection sufficient treatment for posterior fossa ependymomas? J Neurosurg; 2005 Apr;102(4):629-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Those with supratentorial primary lesions, subependymomas, or neuraxis dissemination were excluded.
  • The 10-year actuarial local control rate was 100% for patients who underwent GTR and radiotherapy, 50% for those who underwent GTR alone, and 36% for those who underwent both STR and radiotherapy, representing significant differences between the GTR-plus-radiotherapy and GTR-alone cohorts (p = 0.018), and between the GTR-plus-radiotherapy and the STR-plus-radiotherapy group (p = 0.003).
  • The 10-year overall survival was numerically superior in patients who underwent both GTR and radiotherapy: 83% compared with 67% in those who underwent GTR alone and 43% in those who underwent both STR and radiotherapy.
  • Univariate analyses revealed that radiotherapy, tumor grade, and extent of resection were significant predictors of local control.
  • [MeSH-major] Ependymoma / radiotherapy. Ependymoma / surgery. Infratentorial Neoplasms / radiotherapy. Infratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15871504.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Wen PY: American Society of Clinical Oncology 2010: report of selected studies from the CNS tumors section. Expert Rev Anticancer Ther; 2010 Sep;10(9):1367-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was particular interest in a Phase II study showing that the mTOR inhibitor everolimus had significant activity in tuberous patients with subependymal giant cell astrocytomas.
  • [MeSH-major] Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Immunosuppressive Agents / therapeutic use. Sirolimus / analogs & derivatives. Tuberous Sclerosis / drug therapy

  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836670.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Clinical Conference; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


81. Tay A, Scheithauer BW, Cameron JD, Myhre MJ, Boerner MJ: Retinal ependymoma: an immunohistologic and ultrastructural study. Hum Pathol; 2009 Apr;40(4):578-83
Genetic Alliance. consumer health - Ependymoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal ependymoma: an immunohistologic and ultrastructural study.
  • Most are syndrome associated and include pilocytic astrocytoma in neurofibromatosis type 1 and subependymal giant cell astrocytoma in tuberous sclerosis complex.
  • Acquired, more conventional, diffuse astrocytomas are less frequent.
  • Ependymoma is exquisitely rare.
  • Herein, we report the clinicopathologic features of the second case of retinal ependymoma.
  • The tumor was sporadic in occurrence and unilateral, low grade, and of cellular type.
  • The literature regarding retinal glial neoplasia including ependymoma as well as the so-called massive retinal gliosis is discussed.
  • [MeSH-major] Ependymoma / ultrastructure. Retinal Neoplasms / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18835620.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Gallagher A, Grant EP, Madan N, Jarrett DY, Lyczkowski DA, Thiele EA: MRI findings reveal three different types of tubers in patients with tuberous sclerosis complex. J Neurol; 2010 Aug;257(8):1373-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with Type C tuber dominance have more MRI abnormalities such as subependymal giant cell tumors, and were more likely to have an autism spectrum disorder, a history of infantile spasms, and a higher frequency of epileptic seizures, compared to patients who have a dominance in Type B tubers, and especially to those with a Type A dominance.

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 2000 May 23;54(10):1976-84 [10822440.001]
  • [Cites] Neurology. 2009 Mar 31;72(13):1165-9 [19332694.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Jan;163(1):253-8 [11208653.001]
  • [Cites] Brain Dev. 2001 Nov;23(7):502-7 [11701245.001]
  • [Cites] Eur Radiol. 2002 Jan;12(1):138-43 [11868090.001]
  • [Cites] Epilepsy Res. 2003 Jan;52(3):203-13 [12536053.001]
  • [Cites] Psychol Med. 2003 Feb;33(2):335-44 [12622312.001]
  • [Cites] Arch Neurol. 2003 Nov;60(11):1580-4 [14623730.001]
  • [Cites] Arch Dis Child. 2004 Jun;89(6):530-3 [15155396.001]
  • [Cites] Neurology. 2004 Oct 26;63(8):1457-61 [15505165.001]
  • [Cites] Ann Neurol. 1981 Feb;9(2):174-81 [7235632.001]
  • [Cites] Mayo Clin Proc. 1991 Aug;66(8):792-6 [1861550.001]
  • [Cites] Radiology. 1992 Apr;183(1):227-38 [1549677.001]
  • [Cites] Acta Neuropathol. 1995;90(4):387-99 [8546029.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14152-7 [8943076.001]
  • [Cites] J Child Neurol. 1997 Feb;12(2):85-90 [9075016.001]
  • [Cites] Arch Neurol. 1998 Mar;55(3):379-84 [9520012.001]
  • [Cites] Acta Radiol. 1998 Sep;39(5):482-6 [9755694.001]
  • [Cites] Ann Neurol. 1998 Dec;44(6):858-66 [9851429.001]
  • [Cites] J Child Neurol. 2004 Sep;19(9):643-9 [15563009.001]
  • [Cites] J Child Neurol. 2004 Sep;19(9):650-7 [15563010.001]
  • [Cites] J Child Neurol. 2004 Sep;19(9):658-65 [15563011.001]
  • [Cites] Neurology. 2005 Jul 26;65(2):235-8 [16043792.001]
  • [Cites] Pediatr Radiol. 2006 Feb;36(2):119-25 [16283285.001]
  • [Cites] J Child Neurol. 2005 Oct;20(10):837-41 [16417883.001]
  • [Cites] Pediatr Radiol. 2006 Jun;36(6):498-501 [16568295.001]
  • [Cites] Diagn Interv Radiol. 2006 Jun;12(2):57-60 [16752348.001]
  • [Cites] Epilepsia. 2006 Sep;47(9):1543-9 [16981871.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1345-56 [17005952.001]
  • [Cites] Neurology. 2007 Jan 2;68(1):62-4 [17200495.001]
  • [Cites] Genet Med. 2007 Feb;9(2):88-100 [17304050.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Mar;21(3):557-60 [10730651.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2):189-202 [17637444.001]
  • [Cites] Trends Mol Med. 2007 Aug;13(8):319-26 [17632034.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Oct;28(9):1662-7 [17893226.001]
  • [Cites] Epilepsia. 2008;49 Suppl 2:53-62 [18226172.001]
  • [Cites] Neurology. 2008 Mar 18;70(12):916-23 [18032744.001]
  • [Cites] Neurology. 2008 Mar 18;70(12):908-15 [18032745.001]
  • [Cites] Epilepsia. 2009 Jan;50(1):147-54 [19125835.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):64-80 [11112665.001]
  • (PMID = 20352250.001).
  • [ISSN] 1432-1459
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS024279; None / None / / P01 NS024279-23; United States / NINDS NIH HHS / NS / P01 NS024279-23; Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Other-IDs] NLM/ NIHMS279080; NLM/ PMC3075858
  •  go-up   go-down


83. Wong KK, Tsang YT, Chang YM, Su J, Di Francesco AM, Meco D, Riccardi R, Perlaky L, Dauser RC, Adesina A, Bhattacharjee M, Chintagumpala M, Lau CC: Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array. Cancer Res; 2006 Dec 1;66(23):11172-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide allelic imbalance analysis of pediatric gliomas by single nucleotide polymorphic allele array.
  • Using single nucleotide polymorphic (SNP) allele arrays, we analyzed 28 pediatric gliomas consisting of 14 high-grade gliomas and 14 low-grade gliomas.
  • Most of the low-grade gliomas had no detectable loss of heterozygosity (LOH) in any of the 11,562 SNP loci; exceptions were two gangliogliomas (3q and 9p), one astrocytoma (6q), and two subependymal giant cell astrocytomas (16p and 21q).
  • On the other hand, all high-grade gliomas had various degrees of LOH affecting 52 to 2,168 SNP loci on various chromosomes.
  • This may represent a new molecular mechanism underlying tumor progression.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145861.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA120534
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


84. Reni M, Gatta G, Mazza E, Vecht C: Ependymoma. Crit Rev Oncol Hematol; 2007 Jul;63(1):81-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymoma.
  • Ependymomas are rare tumours of neuroectodermal origin classified as myxopapillary ependymoma and subependymoma (grade I), ependymoma (grade II) and anaplastic ependymoma (grade III).
  • Age <40 years and extent of surgery appear related to better prognosis, while the role of other prognostic factors, such as tumour grade and tumour site are equivocal.
  • Postoperative radiotherapy is indicated in high-grade ependymomas, and is recommended in low-grade ependymomas after subtotal or incomplete resection (confirmed by postoperative MR).
  • Recommended dose to involved fields is 45-54 Gy for low-grade (grade II) and 54-60 Gy for high-grade ependymomas (grade III).
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Infratentorial Neoplasms / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Age Distribution. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Incidence. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Risk Factors. Sex Factors. Survival Analysis

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482475.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  • [Number-of-references] 100
  •  go-up   go-down


85. Ohgaki H, Kim YH, Steinbach JP: Nervous system tumors associated with familial tumor syndromes. Curr Opin Neurol; 2010 Dec;23(6):583-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nervous system tumors associated with familial tumor syndromes.
  • We also briefly review two important advances in this area: the treatment of medulloblastomas in patients with mutations in the PTCH1 gene, and the discovery of deregulated mammalian target of rapamycin as a major oncogenic driver molecule in patients with TSC mutations and subependymal giant cell astrocytoma.
  • [MeSH-major] Genetic Diseases, Inborn / diagnosis. Genetic Diseases, Inborn / genetics. Genetic Predisposition to Disease / genetics. Nervous System Neoplasms / diagnosis. Nervous System Neoplasms / genetics


86. Barton VN, Donson AM, Kleinschmidt-DeMasters BK, Birks DK, Handler MH, Foreman NK: Unique molecular characteristics of pediatric myxopapillary ependymoma. Brain Pathol; 2010 May;20(3):560-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique molecular characteristics of pediatric myxopapillary ependymoma.
  • Myxopapillary ependymoma (MEPN) generally can be cured by gross total surgical resection and usually manifest a favorable prognosis.
  • Clinical trial design requires a better understanding of tumor biology.
  • Unique molecular features of MEPN were investigated by using microarray technology to compare the gene expression of five pediatric MEPN to 24 pediatric intracranial ependymoma (EPN).
  • Protein expression in MEPN was compared to subependymoma, spinal EPN, intracranial EPN and normal fetal and adult ependyma.
  • Immunoreactivity for HOXB13, NEFL and PDGFR alpha was strongest in MEPN and virtually absent in subependymoma.
  • [MeSH-major] Ependymoma / genetics. Ependymoma / metabolism. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism. Spinal Cord Neoplasms / genetics. Spinal Cord Neoplasms / metabolism

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Myxopapillary ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 2000 Jan;32(1):30-6 [10765136.001]
  • [Cites] Cancer. 2009 Sep 1;115(17):3955-68 [19536879.001]
  • [Cites] Med Pediatr Oncol. 2000 Oct;35(4):443-5 [11025481.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):279-84 [11682119.001]
  • [Cites] Prostate. 2002 Feb 15;50(3):162-9 [11813208.001]
  • [Cites] Leukemia. 2002 Feb;16(2):186-95 [11840284.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Exp Cell Res. 2004 Feb 1;293(1):144-53 [14729064.001]
  • [Cites] Acta Neurochir (Wien). 2004 Nov;146(11):1255-8 [15365794.001]
  • [Cites] J Surg Oncol. 1983 Jan;22(1):33-6 [6823114.001]
  • [Cites] Cell. 1984 Oct;38(3):667-73 [6091895.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):31-6 [2909684.001]
  • [Cites] Nucleic Acids Res. 1989 Dec 25;17(24):10385-402 [2574852.001]
  • [Cites] Childs Nerv Syst. 1991 Aug;7(4):177-82 [1933913.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):237-44 [7678830.001]
  • [Cites] Childs Nerv Syst. 1993 Feb;9(1):3-6 [8481942.001]
  • [Cites] Acta Neurochir (Wien). 1993;124(2-4):99-103 [8304078.001]
  • [Cites] Pediatr Neurosurg. 1998 May;28(5):273-8 [9732262.001]
  • [Cites] Pediatr Neurosurg. 1998 Jun;28(6):314-9 [9782208.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3045-50 [9865919.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):953-8 [9869215.001]
  • [Cites] Leukemia. 1999 May;13(5):687-98 [10374871.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):627-32 [10433955.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):25-8 [15803371.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):59-64 [16206735.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5223-33 [17114655.001]
  • [Cites] Acta Neuropathol. 2007 Mar;113(3):325-37 [17265049.001]
  • [Cites] J Neurooncol. 2007 May;83(1):85-9 [17206474.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5806-13 [17575148.001]
  • [Cites] Dev Dyn. 2007 Sep;236(9):2454-63 [17685480.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Aug;66(8):740-9 [17882018.001]
  • [Cites] Cancer Invest. 2008 Dec;26(10):990-8 [19093257.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):470-5 [19156136.001]
  • [Cites] Expert Opin Ther Targets. 2009 Apr;13(4):443-54 [19335066.001]
  • [Cites] Neurosurg Rev. 2009 Jul;32(3):321-34; discussion 334 [19221818.001]
  • [Cites] Nature. 2000 Jun 22;405(6789):974-8 [10879542.001]
  • (PMID = 19793339.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ PMC2871180
  •  go-up   go-down


87. Abel TW, Curtis M, Lin DD, Burger PC, Cummings TJ: Complex choristoma of the gyrus rectus: a distinct clinicopathologic entity? Am J Surg Pathol; 2006 May;30(5):625-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In some areas, the epithelial structures were separated by reactive glial tissue resembling pilocytic astrocytoma, with prominent, piloid processes, Rosenthal fibers, and gemistocytic astrocytes.
  • In other areas, glial nuclei formed small clusters reminiscent of subependymoma, but no glioma was identified in either case.
  • Follow-up interval of up to 2 years showed no evidence of recurrent tumor.

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16699317.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Daou MC, Smith TW, Litofsky NS, Hsieh CC, Ross AH: Doublecortin is preferentially expressed in invasive human brain tumors. Acta Neuropathol; 2005 Nov;110(5):472-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DCX was highly expressed in both high-grade invasive tumors (glioblastoma, n=11; anaplastic astrocytoma/oligoastrocytoma, n=7; and medulloblastoma/PNET, n=6) and low-grade invasive tumors (oligodendroglioma, n=3; and astrocytoma/oligoastrocytoma, n=5).
  • However, DCX was less intensely expressed in the circumscribed group of tumors (pilocytic astrocytoma, n=6; ependymoma/subependymoma, n=7; dysembryoplastic neuroepithelial tumor, n=4; ganglioglioma, n=2; meningioma, n=9; and schwannoma, n=9).
  • By the Cochran-Mantel-Haenszel statistical test, the circumscribed group was significantly different from both the high-grade invasive group (P<0.0001) and the low-grade invasive group (P<0.0001).
  • In addition, DCX immunostaining was stronger at the margin of the tumor than at the center.
  • DCX mRNA and protein was detected in glioma cell lines by Northern blotting, immunofluorescence microscopy and Western blotting.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16195916.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS021716; United States / NCI NIH HHS / CA / R21 CA107372; United States / NCI NIH HHS / CA / CA-10737; United States / NINDS NIH HHS / NS / NS-21716
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Microtubule-Associated Proteins; 0 / Neuropeptides; 0 / RNA, Messenger; 0 / doublecortin protein
  •  go-up   go-down


89. Yanni DS, Ulkatan S, Deletis V, Barrenechea IJ, Sen C, Perin NI: Utility of neurophysiological monitoring using dorsal column mapping in intramedullary spinal cord surgery. J Neurosurg Spine; 2010 Jun;12(6):623-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 4 ependymomas, 1 subependymoma, 1 gangliocytoma, 1 anaplastic astrocytoma, 1 cavernous malformation, and 2 symptomatic syringes requiring shunting.
  • [MeSH-minor] Adult. Aged. Electrodes. Ependymoma / surgery. Evoked Potentials, Motor / physiology. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515347.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Rodriguez FJ, Scheithauer BW, Perry A, Oliveira AM, Jenkins RB, Oviedo A, Mork SJ, Palmer CA, Burger PC: Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic study. Am J Surg Pathol; 2008 May;32(5):699-709
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic study.
  • Sarcomatous change occurring in ependymal tumors is rare.
  • At presentation, the sarcomatous component was noted in 6 (of 10) cases and the ependymal element was grade III in 7 and grade II in 3 tumors, respectively.
  • The single case involving the fourth ventricle/left cerebellopontine angle consisted of subependymoma and fibrosarcoma components in roughly equal proportions at presentation.
  • Fluorescence in situ hybridization studies performed with probes targeting the NF2 gene and other members of the protein 4.1 gene family demonstrated similar alterations in the ependymal and sarcomatous components in the cases tested, including polysomies/polyploidy (n=3), gains of 1q (n=3), deletions of 22q (n=2) and 6q (n=1), and monosomy 18 (n=1).
  • On follow-up, 5 patients expired 4 months to 18 years after initial resection and 4 to 11 months after development of the sarcomatous component (mean, 7.6 mo); 1 patient is alive at 5 years with recurrent disease, and 1 is alive without recurrence 12 years after initial gross total resection followed by radiation therapy.
  • Although rare, ependymal neoplasms must be included among the gliomas prone to undergo sarcomatous change and we propose the term "ependymosarcoma" for these tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / secondary. Fibrosarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chromosome Aberrations. Combined Modality Therapy. DNA, Neoplasm / analysis. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18347506.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


91. Franken SP, Setz-Pels W, Smink-Bol M, Gijtenbeek JM, Nanda D, Van Der Maazen RW, Van Der Vliet T, Bussink J: Unusual case of bifocal leptomeningeal melanocytoma in the posterior fossa with seeding in the spinal canal. Br J Radiol; 2009 Aug;82(981):e182-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The radiological differential diagnoses included multiple meningiomas, schwannomas, neurofibromas and subependymomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19729548.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Shuangshoti S, Rushing EJ, Mena H, Olsen C, Sandberg GD: Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients. Cancer; 2005 Jun 15;103(12):2598-605
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients.
  • BACKGROUND: Published research on the clinicopathologic features of extraventricular ependymal neoplasms of the cerebral hemispheres has been scant.
  • RESULTS: Among these 32 cases were 2 subependymomas, 19 ependymomas, and 11 anaplastic ependymomas.
  • Ki-67 proliferation index paralleled tumor grade.
  • Immunoreactivity for p53 protein was observed in the 2 cases of subependymoma, in 10 of 11 anaplastic ependymomas, and in 6 of 17 ependymomas.
  • CONCLUSIONS: The results of the current study suggest that there is no significant relation between histopathology, Ki-67 proliferation index, p53 immunolabeling, tumor ploidy, and biologic behavior.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Glioma, Subependymal / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Ki-67 Antigen / metabolism. Male. Middle Aged. Ploidies. Prognosis. S Phase. Tumor Suppressor Protein p53

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2005 by the American Cancer Society.
  • (PMID = 15861411.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


93. Maliszewski M, Majchrzak H: [Operative treatment of the intramedullary tumors with the methylprednisolone usage--preliminary report]. Wiad Lek; 2006;59(7-8):481-5
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroprotection of the spinal cord in the course of treatment included: determining operational tactics on the basis of magnetic resonance imaging (MRI) performed in three planes, using MP according to NASCIS II and in maintenance dose in the 2-7 day after the operation, SSEP monitoring, myelotomy in the form of anatomical preparation of the posterior longitudinal fissure, sparing big transverse branches of the vasocorona of the posterior column, debulking of the tumor with an ultrasonic aspirator or CO2 laser, closure of the spinal cord after the removal of the tumor with pial sutures and sutures of the arachnoidea.
  • RESULTS: Among the operated tumors 16 had a clear border, the remaining ones were 14 astrocytomas of varying malignancy and infiltration of the white matter of the spinal cord and 3 lipomas.
  • [MeSH-major] Astrocytoma / surgery. Glioma, Subependymal / surgery. Methylprednisolone / administration & dosage. Neuroprotective Agents / administration & dosage. Neurosurgical Procedures / methods. Spinal Cord Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17209343.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Neuroprotective Agents; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


94. Gilhuis HJ, van der Laak JA, Pomp J, Kappelle AC, Gijtenbeek JM, Wesseling P: Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes. Angiogenesis; 2006;9(4):201-8
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional (3D) reconstruction and quantitative analysis of the microvasculature in medulloblastoma and ependymoma subtypes.
  • In the World Health Organisation (WHO) classification of tumours of the nervous system, four main histopathological subtypes of medulloblastomas (classic medulloblastoma, desmoplastic medulloblastoma, medulloblastoma with extensive nodularity and advanced neuronal differentiation and large cell/anaplastic medulloblastoma) as well as of ependymal tumours (low-grade ependymoma, anaplastic ependymoma, myxopapillary ependymoma and subependymoma) are recognised.
  • Under the hypothesis that the microvascular architecture of tumours is a reflection of the histopathological subtype, we performed three-dimensional reconstructions of the microvasculature in these subtypes of medulloblastomas and ependymal tumours using computerised image analysis.
  • Three-dimensional analysis of ependymal tumours showed that low-grade ependymoma had larger but fewer vessels compared to anaplastic ependymoma, while myxopapillary ependymoma had a complex, heterogeneous pattern of vessels and subependymoma few but regular vessels.
  • In ependymal tumours, the highest values for vessel number, vessel area and vessel perimeter were found in anaplastic ependymoma and the lowest values in subependymoma.
  • We conclude that our three-dimensional reconstructions shed unprecedented light on the tumour vasculature in medulloblastomas and ependymal tumours and expect that such reconstructions are helpful tools for further studies on tumour angiogenesis.
  • [MeSH-major] Cerebellar Neoplasms / blood supply. Ependymoma / blood supply. Medulloblastoma / blood supply. Models, Biological

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17109194.001).
  • [ISSN] 0969-6970
  • [Journal-full-title] Angiogenesis
  • [ISO-abbreviation] Angiogenesis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


95. Rivera VM: Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery. Brain Inj; 2005 Aug 20;19(9):725-7
Hazardous Substances Data Bank. MODAFINIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PRIMARY OBJECTIVE: This case report reviews the history and post-operative status of a 77-year-old woman who underwent transcallosal resection of an intra-ventricular haemorrhagic subependymoma and who remained in a deep post-operative state of lethargy and listlessness.
  • [MeSH-minor] Aged. Cerebral Ventricle Neoplasms / surgery. Female. Glioma, Subependymal / surgery. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16195186.001).
  • [ISSN] 0269-9052
  • [Journal-full-title] Brain injury
  • [ISO-abbreviation] Brain Inj
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Central Nervous System Stimulants; R3UK8X3U3D / modafinil
  •  go-up   go-down


96. Adamek D, Dec M, Sobol G, Urbanowicz B, Jaworski M: Giant cell ependymoma: a case report. Clin Neurol Neurosurg; 2008 Feb;110(2):176-81
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell ependymoma: a case report.
  • A peculiar variant of ependymoma known as "giant cell ependymoma" ("GCE") is especially rarely reported, it may pose some difficulties for the diagnosing neuropathologist.
  • Here we present a case of a giant cell ependymoma occuring in a 17-year-old patient with the history of 2-year recurrent headaches and a 1-month history of vision impairment.
  • Histological, immunohistochemical and electron microscopic findings were consistent with high-grade ependymoma.
  • Especially striking was the presence of bizzare pleomorphic giant cells which predominated in the tumor tissue.
  • This type of neoplasm necessitates, at least in theory, differentiation with anaplastic oligodendroglioma, clear cell ependymoma, pleomorphic xanthoastrocytoma, giant cell glioblastoma, and subependymal giant cell astrocytoma.
  • In spite of apparently "worrisome" histology GCE seems to be a neoplasm with a relatively good prognosis.
  • [MeSH-major] Brain Neoplasms / pathology. Ependymoma / pathology. Lateral Ventricles

  • Genetic Alliance. consumer health - Ependymoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006220.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


97. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR: Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol; 2006 Mar;59(3):490-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapamycin causes regression of astrocytomas in tuberous sclerosis complex.
  • OBJECTIVE: Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the formation of hamartomas in multiple organs.
  • Five to 15% of affected individuals display subependymal giant cell astrocytomas, which can lead to substantial neurological and postoperative morbidity due to the production of hydrocephalus, mass effect, and their typical location adjacent to the foramen of Monro.
  • We sought to see whether therapy with oral rapamycin could affect growth or induce regression in astrocytomas associated with TSC.
  • METHODS: Five subjects with clinically definite TSC and either subependymal giant cell astrocytomas (n = 4) or a pilocytic astrocytoma (n = 1) were treated with oral rapamycin at standard immunosuppressive doses (serum levels 5-15 ng/ml) from 2.5 to 20 months.
  • Interruption of therapy resulted in regrowth of subependymal giant cell astrocytomas in one patient.
  • INTERPRETATION: Oral rapamycin therapy can induce regression of astrocytomas associated with TSC and may offer an alternative to operative therapy of these lesions.
  • [MeSH-major] Astrocytoma / drug therapy. Astrocytoma / etiology. Brain Neoplasms / drug therapy. Immunosuppressive Agents. Regression (Psychology). Sirolimus / therapeutic use. Tuberous Sclerosis / complications


98. Santagata S, Tuli S, Wiese DE 2nd, Day A, De Girolami U: Intramedullary neuroma of the cervicomedullary junction. Case report. J Neurosurg Spine; 2006 Oct;5(4):362-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors report the case of a 50-year-old man who had been involved in a motor vehicle accident, during which his car was struck from behind as it was stationary at an intersection, more than 5 years before presentation.
  • The imaging features of the lesion raised the question of an ependymoma or subependymoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048775.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Waldau B, McLendon RE, Fuchs HE, George TM, Grant GA: Few isolated neurons in hypothalamic hamartomas may cause gelastic seizures. Pediatr Neurosurg; 2009;45(3):225-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypothalamic hamartomas (HHs) are congenital, benign masses in the hypothalamus and tuber cinereum that may cause central precocious puberty and gelastic seizures.
  • Here we describe the case of a 5-year-old boy with gelastic seizures who underwent resection of a HH that contained nodules of glial cells, but only few, randomly distributed neurons.
  • This finding is clinically important since hypothalamic hamartomas with rare neurons can easily be misdiagnosed as pilocytic astrocytomas or subependymomas if their presence is overlooked.

  • Genetic Alliance. consumer health - Hypothalamic hamartomas.
  • Genetic Alliance. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19521137.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


100. Szeliga M, Matyja E, Obara M, Grajkowska W, Czernicki T, Albrecht J: Relative expression of mRNAS coding for glutaminase isoforms in CNS tissues and CNS tumors. Neurochem Res; 2008 May;33(5):808-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our previous study showed that human malignant gliomas (WHO grades III and IV) lack expression of LGA mRNA but are enriched in GAC mRNA relative to KGA mRNA.
  • Here we analyzed the expression of mRNAs coding for the three isoforms in the biopsy material derived from other central nervous system tumors of WHO grades I-III.
  • The GAC mRNA/KGA mRNA expression ratio was as a rule higher in the neoplastic than in control tissues, irrespective of the cell type dominating in the tumor or tumor malignancy.
  • LGA mRNA expression was relatively very low in cultured astrocytes, and very low to absent in astrocytoma pilocyticum, ependymoma and subependymal giant cell astrocytoma (SEGA), tumors of astrocytic origin.
  • The results show that low expression of LGA mRNA is a feature common to normal astrocytes and astroglia-derived tumor cells or ependymomas and can be considered as a cell-type, rather than a malignancy marker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroscience. 1999;88(4):1137-51 [10336125.001]
  • [Cites] Physiol Genomics. 2002;9(3):157-66 [12045296.001]
  • [Cites] Neurochem Int. 2006 May-Jun;48(6-7):465-71 [16516349.001]
  • [Cites] Physiol Genomics. 1999 Aug 31;1(2):51-62 [11015561.001]
  • [Cites] J Bioenerg Biomembr. 1998 Dec;30(6):565-78 [10206476.001]
  • [Cites] Neurochem Res. 1988 Apr;13(4):383-8 [2899301.001]
  • [Cites] Mol Cell Biochem. 1992 Jul 6;113(1):1-15 [1640933.001]
  • [Cites] Biochem J. 2000 Jun 1;348 Pt 2:257-61 [10816417.001]
  • [Cites] Neurosci Lett. 2005 Feb 21;374(3):171-3 [15663956.001]
  • [Cites] Biochem J. 2000 Jan 15;345 Pt 2:365-75 [10620514.001]
  • [Cites] Biochem J. 2003 Mar 1;370(Pt 2):403-8 [12408749.001]
  • [Cites] J Neurosci Res. 2001 Dec 1;66(5):951-8 [11746423.001]
  • [Cites] Annu Rev Nutr. 1995;15:133-59 [8527215.001]
  • [Cites] Biochem J. 2005 Mar 15;386(Pt 3):535-42 [15496140.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1192-4 [1346587.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38939-44 [12163477.001]
  • [Cites] Ann Surg. 1993 Dec;218(6):715-28 [8257221.001]
  • [Cites] FEBS Lett. 1994 Mar 14;341(1):39-42 [8137919.001]
  • (PMID = 17940881.001).
  • [ISSN] 0364-3190
  • [Journal-full-title] Neurochemical research
  • [ISO-abbreviation] Neurochem. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / RNA, Messenger; EC 3.5.1.2 / Glutaminase
  •  go-up   go-down






Advertisement